<?xml version="1.0" ?>
<document version="1.8" entity_encoding="single">
  <page number="1">
    <text>**HAEMATOPOIETIC STEM CELL TRANSPLANTS**

2026 DENT5311 DMD3
SPECIAL NEEDS DENTISTRY MODULE

DR JEE-YUN LEUNG

BDSC(HONS) MSC(SCD) DSCD(RCSENG) DCLINDENT(SND) MRACDS(SND) FANZASND</text>
    <formatted_text>2026 DENT5311 DMD3

Special Needs Dentistry Module

Dr Jee-Yun Leung

BDSc(Hons), MSc(SCD), DScD(RCSEng), DClinDent(SND), MRACDS(SND), FANZASND</formatted_text>
  </page>
  <page number="2">
    <text># LECTURE OUTCOMES

1. UNDERSTAND THE TYPES OF, AND COMMON INDICATIONS FOR, HSCT/BMT

2. OUTLINE THE PATIENT JOURNEY TO HSCT/BMT

3. DESCRIBE THE ORAL COMPLICATIONS OF HSCT/BMT, AND BASIC ORAL CARE BEFORE, DURING AND AFTER TRANSPLANT

4. DISCUSS THE SYSTEMIC AND ORAL MANIFESTATIONS OF GRAFT VS HOST DISEASE, AND APPRECIATE ITS MANAGEMENT OPTIONS

5. APPRECIATE THE DENTAL WORK-UP REQUIRED PRIOR TO STEM CELL TRANSPLANT

![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_6bf50ecf1b35c5c5.webp)</text>
    <formatted_text>1. Understand the types of, and common indications for, HSCT/BMT

2. Outline the patient journey to HSCT/BMT

3. Describe the oral complications of HSCT/BMT, and basic oral care before, during and after transplant

4. Discuss the systemic and oral manifestations of graft vs host disease, and appreciate its management options

5. Appreciate the dental work-up required prior to stem cell transplant</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:00:03" confidence="2" anchor="5. Appreciate the dental work-up required prior to stem cell transplant">
- ==Modifications required to safely provide dental treatment==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="491,276,943,713" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_6bf50ecf1b35c5c5.webp">
        <description>A photograph showing three glass Erlenmeyer flasks arranged in a row against a white background. A blue pipette is shown dripping a dark blue substance into the liquid of the leftmost flask, while the other two flasks contain varying stages of blue dye dispersing and mixing within clear fluid.</description>
      </img>
    </images>
  </page>
  <page number="3">
    <text>HAEMATOPOIETIC
STEM CELL
TRANSPLANT

The process of transplanting healthy blood-forming cells into an individual to replace cells that have been destroyed by disease, radiation or cytotoxic drugs

![Timeline of Hematopoietic Stem Cell Transplantation](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_bcef44d00b404ff2.webp)</text>
    <formatted_text>The process of transplanting healthy blood-forming cells into an individual to replace cells that have been destroyed by disease, radiation or cytotoxic drugs.</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:00:59" confidence="15" anchor="The process of transplanting healthy blood-forming cells into an individual to r">

&gt; [!note] Lecturer — Transplant Use
&gt; Stem cell transplantation was previously considered a treatment of last resort, but its use has increased.
&gt;
&gt; - Peripheral blood stem cell transplantation and more rapid engraftment have contributed to this increase.
&gt; - Reduced-intensity conditioning regimens and increasing numbers of patients suitable for transplantation have also expanded its use.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="450,370,931,674" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_bcef44d00b404ff2.webp" caption="Timeline of Hematopoietic Stem Cell Transplantation">
        <description>A dual-axis line chart plotting the number of hematopoietic stem cell transplants from 1955 to 2010, distinguishing between autologous and allogeneic procedures. A timeline axis along the bottom annotates key historical milestones in transplant medicine, such as 'Twin-twin transplantations' (1960), 'HLA skin-grafting experiments' (1965), and 'Cure of thalassemia with BMT' (1985). The graph illustrates a sharp increase in procedure volume starting around 1980.</description>
      </img>
    </images>
  </page>
  <page number="4">
    <text>HAEMATOPOIETIC STEM CELL TRANSPLANT

| Definitions &amp; Abbreviations |  |
| :--- | :--- |
| Graft | Donated organ/tissue |
| Host | Person who receives donor organs/tissues |
| Autograft | Organs/tissues that are transplanted within the same individual |
| Allograft | Organs/tissues that are transplanted into a different person |
| HSCT | Haematopoietic stem cell transplantation (PBSCT or BMT) |
| PBSCT | Peripheral blood stem cell transplant (stem cells harvested from peripheral circulating blood) |
| BMT | Bone marrow transplant (stem cells harvested from donor bone marrow) |
| Rejection | Host immune system mounts defence against grafted tissue leading to graft destruction |
| GvHD | Grafted tissue mounts an immune defence against the host cells |

![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_a3265f1a645cdd70.webp)</text>
    <formatted_text>| Term | Definition |
| :--- | :--- |
| Graft | Donated organ/tissue |
| Host | Person who receives donor organs/tissues |
| Autograft | Organs/tissues that are transplanted within the same individual |
| Allograft | Organs/tissues that are transplanted into a different person |
| HSCT | Haematopoietic stem cell transplantation (PBSCT or BMT) |
| PBSCT | Peripheral blood stem cell transplant (stem cells harvested from peripheral circulating blood) |
| BMT | Bone marrow transplant (stem cells harvested from donor bone marrow) |
| Rejection | Host immune system mounts defence against grafted tissue leading to graft destruction |
| GvHD | Grafted tissue mounts an immune defence against the host cells |</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:02:38" confidence="10" anchor="GvHD | Grafted tissue mounts an immune defence against the host cells">

&gt; [!note] Lecturer — Rejection and GvHD
&gt; Rejection occurs when the host immune system recognises the graft as foreign and attacks it, whereas graft-versus-host disease occurs when donor-derived immune cells attack host tissues.
&gt;
&gt; - In rejection, the host attacks the graft.
&gt; - In GVHD, the graft attacks the host.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="82,371,888,708" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_a3265f1a645cdd70.webp">
        <description>A two-column table titled &quot;Definitions &amp; Abbreviations&quot; that lists key terms related to transplantation. The left column contains terms such as Graft, Host, Autograft, Allograft, HSCT, PBSCT, BMT, Rejection, and GvHD, while the right column provides their corresponding definitions.</description>
      </img>
    </images>
  </page>
  <page number="5">
    <text>TYPES AND INDICATIONS

Haematopoietic stem cell transplants</text>
    <formatted_text>Haematopoietic stem cell transplants.</formatted_text>
    <images>
      <img order="0" bbox="0,133,1000,388" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>Decorative graphic showing a pattern of translucent blue bubbles or spheres against a white background.</description>
      </img>
    </images>
  </page>
  <page number="6">
    <text>TYPES OF STEM CELL TRANSPLANT

(1) source of the stem cells, (2) donor type, (3) the conditioning regimen</text>
    <formatted_text>Stem cell transplants are classified by:

1. Source of the stem cells
2. Donor type
3. The conditioning regimen</formatted_text>
  </page>
  <page number="7">
    <text>1) SOURCE OF STEM CELLS

| Peripheral blood | Bone marrow | Umbilical cord blood |
| :--- | :--- | :--- |
| • Preferred method of harvest&lt;br&gt;• Administration of G-CSF → harvest from peripheral blood circulation&lt;br&gt;• Advantages: superior engraftment, reduced early infection, shorter hospitalisation&lt;br&gt;• Disadvantages: higher incidence of GVHD and CMV infection | • Aspiration of bone marrow tissue from posterior iliac crest&lt;br&gt;• Advantages: lower incidence GVHD, less immunosuppression&lt;br&gt;• Disadvantages: frequently complicated by mild back or hip pain, fatigue, transient changes in peripheral blood cell counts | • Predominantly for paediatric setting (low volume of available cells)&lt;br&gt;• Advantages: less stringent matching required, expanded donor pool, ease of procurement, less GVHD&lt;br&gt;• Disadvantages: slower engraftment, increased graft failure, unavailability of donor for additional donations |</text>
    <formatted_text>#### Peripheral blood

- Preferred method of harvest
- Administration of G-CSF → harvest from peripheral blood circulation
- Advantages: superior engraftment, reduced early infection, shorter hospitalisation
- Disadvantages: higher incidence of GVHD and CMV infection

#### Bone marrow

- Aspiration of bone marrow tissue from posterior iliac crest
- Advantages: lower incidence of GVHD, less immunosuppression
- Disadvantages: frequently complicated by mild back or hip pain, fatigue, transient changes in peripheral blood cell counts

#### Umbilical cord blood

- Predominantly for paediatric setting (low volume of available cells)
- Advantages: less stringent matching required, expanded donor pool, ease of procurement, less GVHD
- Disadvantages: slower engraftment, increased graft failure, unavailability of donor for additional donations</formatted_text>
    <audio_inserts count="3">
      <insert timestamp="00:04:03" confidence="7" anchor="- Advantages: superior engraftment, reduced early infection, shorter hospitalisa">
- ==G-CSF stimulates granulocyte production and mobilises stem cells into the circulating blood.==
- ==Earlier recovery of granulocytes and platelets than with bone marrow.==
- ==Reduced cost compared with bone marrow transplantation.==
- ==Lower complication rates associated with mobilisation and collection.==</insert>
      <insert timestamp="00:04:36" confidence="7" anchor="- Advantages: lower incidence of GVHD, less immunosuppression
- Disadvantages: f">
- ==Bone marrow is collected from the posterior iliac crest while the donor is under anaesthesia.==
- ==The graft contains fewer T cells than a peripheral blood graft, reducing the incidence and severity of acute and chronic GVHD.==
- ==Bone marrow is commonly used for non-malignant disease, including aplastic anaemia.==</insert>
      <insert timestamp="00:06:18" confidence="6" anchor="- Advantages: less stringent matching required, expanded donor pool, ease of pro">
- ==Cord blood has minimal donor risk and no donor attrition.==
- ==Cord blood may have delayed immune reconstitution.==
- ==Cord blood from two matching donors may be required in some cases.==
- ==The donor is unavailable for additional donations such as donor lymphocyte infusion if the transplant fails.==</insert>
    </audio_inserts>
  </page>
  <page number="8">
    <text>&lt;h2&gt;2) DONOR TYPES&lt;/h2&gt;

&lt;ul&gt;
  &lt;li&gt;Autologous (self)&lt;/li&gt;
  &lt;li&gt;Allogeneic (other)
    &lt;ul&gt;
      &lt;li&gt;Matched donors&lt;/li&gt;
      &lt;li&gt;Haplo-identical donor&lt;/li&gt;
    &lt;/ul&gt;
  &lt;/li&gt;
  &lt;li&gt;Syngeneic (identical twin)&lt;/li&gt;
&lt;/ul&gt;

&lt;table&gt;
  &lt;tr&gt;
    &lt;th&gt;&lt;/th&gt;
    &lt;th&gt;Autologous&lt;/th&gt;
    &lt;th&gt;Allogeneic&lt;/th&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Cell source&lt;/td&gt;
    &lt;td&gt;Patient’s own cells&lt;/td&gt;
    &lt;td&gt;Related or unrelated donor&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;GVHD&lt;/td&gt;
    &lt;td&gt;Rare&lt;/td&gt;
    &lt;td&gt;High risk; donor cells may attack host&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;GVT effect&lt;/td&gt;
    &lt;td&gt;None&lt;/td&gt;
    &lt;td&gt;Present; donor cells attack cancer&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Immune recovery&lt;/td&gt;
    &lt;td&gt;Faster (3-6 months)&lt;/td&gt;
    &lt;td&gt;Slower (12-18 months), requires immunosuppressants&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Risk of relapse&lt;/td&gt;
    &lt;td&gt;Higher&lt;/td&gt;
    &lt;td&gt;Lower (due to GVT effect)&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td&gt;Primary goal&lt;/td&gt;
    &lt;td&gt;Prepares the body to tolerate high-dose chemo for responsive cancers&lt;/td&gt;
    &lt;td&gt;Treat cancers less responsive to chemo, but vulnerable to attack with a new immune system from donor stem cells&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_051273ddf4ca25dc.webp)</text>
    <formatted_text>- Autologous (self)
- Allogeneic (other)
  - Matched donors
  - Haplo-identical donor
- Syngeneic (identical twin)

| | Autologous | Allogeneic |
| :--- | :--- | :--- |
| Cell source | Patient's own cells | Related or unrelated donor |
| GVHD | Rare | High risk; donor cells may attack host |
| GVT effect | None | Present; donor cells attack cancer |
| Immune recovery | Faster (3–6 months) | Slower (12–18 months), requires immunosuppressants |
| Risk of relapse | Higher | Lower (due to GVT effect) |
| Primary goal | Prepares the body to tolerate high-dose chemo for responsive cancers | Treat cancers less responsive to chemo, but vulnerable to attack with a new immune system from donor stem cells |</formatted_text>
    <images>
      <img order="0" bbox="363,360,942,822" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_051273ddf4ca25dc.webp">
        <description>A comparison table contrasting Autologous and Allogeneic donor types across six clinical parameters: cell source, GVHD risk, GVT effect, immune recovery timeline, relapse risk, and primary therapeutic goal.</description>
      </img>
    </images>
  </page>
  <page number="9">
    <text>2) DONOR TYPES

Chromosome 6
p-arm
q-arm

MHC class I
F G A E C B

MHC class II
DR DQ DP

CD4
T Cell
CD8
A1 B8 B44 Cw1 Cw6
A3
HLA-B
B8,B44
HLA-C
Cw1,Cw6
HLA-A
A1,A3
APC Cell

CD8
CD4
T Cell
DR6 DP11 DP17 DQ4 DQ7
DR1
HLA-DR
DR1,DR6
HLA-DP
DP11,DP17
HLA-DQ
DQ4,DQ7
APC Cell

HLA
HLA-Class II HLA-Class I

Matching = HLA complex (human leukocyte antigen) / MHC (major histocompatibility complex)

![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_6423c2ee65c25026.webp)
![The Major Histocompatibility Complex &amp; Antigen recognition](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_7d5dc8b565c7c45f.webp)</text>
    <formatted_text>#### Chromosome 6 — HLA regions

- **MHC class I:** HLA-A (A1, A3), HLA-B (B8, B44), HLA-C (Cw1, Cw6)
- **MHC class II:** HLA-DR (DR1, DR6), HLA-DP (DP11, DP17), HLA-DQ (DQ4, DQ7)
- Gene loci on the p-arm and q-arm: F, G, A, E, C, B (class I); DR, DQ, DP (class II)

#### Antigen presentation

- APC cell presents HLA class I antigens (A1, A3; B8, B44; Cw1, Cw6) to CD8 and CD4 T cells
- APC cell presents HLA class II antigens (DR1, DR6; DP11, DP17; DQ4, DQ7) to CD4 and CD8 T cells

Matching = HLA complex (human leukocyte antigen) / MHC (major histocompatibility complex)</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:10:17" confidence="6" anchor="Gene loci on the p-arm and q-arm: F, G, A, E, C, B (class I); DR, DQ, DP (class ">

&gt; [!note] Lecturer — HLA Function
&gt; HLA is a cell-surface marker found on most cells that the immune system uses to distinguish self from foreign cells.
&gt;
&gt; - If T cells recognise an antigen as self, they do not respond; recognition as foreign may trigger an immune response.
&gt; - Depending on the transplant centre, matching may use eight-out-of-eight, ten-out-of-ten, or twelve-out-of-twelve criteria.
</insert>
      <insert timestamp="00:12:11" confidence="9" anchor="Matching = HLA complex (human leukocyte antigen) / MHC (major histocompatibility">

&gt; [!note] Lecturer — Minor Histocompatibility
&gt; Even when major HLA markers are well matched, mismatched minor histocompatibility complex genes can cause rejection or GVHD.
&gt;
&gt; - Immunosuppressive regimens are therefore required for allogeneic transplantation.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="125,330,386,680" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_6423c2ee65c25026.webp">
        <description>This diagram illustrates the genetic location of the Major Histocompatibility Complex (MHC) on Chromosome 6. It depicts a karyotype of the chromosome with p-arm and q-arm labels, zooming in to show that MHC class I genes (labeled F, G, A, E, C, B) are located on the short arm (p-arm), while MHC class II genes (labeled DR, DQ, DP) are located on the long arm (q-arm).</description>
      </img>
      <img order="1" bbox="444,361,911,678" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_7d5dc8b565c7c45f.webp" caption="The Major Histocompatibility Complex &amp; Antigen recognition">
        <description>This labelled diagram illustrates antigen recognition by T cells, depicting interactions between a CD4+ T cell and an APC cell presenting HLA-Class II molecules (HLA-DR, DP, DQ) on the left, and a CD8+ T cell interacting with an APC cell presenting HLA-Class I molecules (HLA-A, B, C) on the right. Specific allele labels such as A1, A3, B8, B44, DR1, and DP11 are visible on the receptors to denote the major histocompatibility complex variants involved in the binding process.</description>
      </img>
    </images>
  </page>
  <page number="10">
    <text>HLA MATCH – BONE
MARROW STEM CELLS

• Allogeneic (other)
  • Matched donors
    • Matched related donor -&gt; Siblings have 1/4 chance
    • Matched unrelated donor
  • Haplo-identical donor

Bone marrow graft
Recipient
A
C
B
DRB1
DPB1
DQB1

Donor hierarchy:
1. Matched sibling
2. Matched unrelated

3. Mismatched donors:
Haploidentical
Unrelated (7/8)
Cord

A
C
B
DRB1
DPB1
DQB1
High resolution
High resolution
High resolution
High resolution
High resolution
High resolution

![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_aec3b68c6369fab2.webp)</text>
    <formatted_text>#### Donor hierarchy

1. Matched sibling
2. Matched unrelated
3. Mismatched donors:
   - Haploidentical
   - Unrelated (7/8)
   - Cord

- Allogeneic (other)
  - Matched donors
    - Matched related donor → siblings have 1/4 chance
    - Matched unrelated donor
  - Haplo-identical donor

**Loci tested (high resolution):** HLA-A, HLA-C, HLA-B, DRB1, DPB1, DQB1 — assessed between bone marrow graft donor and recipient.</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:12:55" confidence="12" anchor="- Haplo-identical donor">
    - ==Haploidentical transplantation uses high-dose chemotherapy several days after transplantation to reduce active T cells and minimise GVHD.==
    - ==An identical twin donor is described as a syngeneic transplant; these patients do not develop GVHD but have less graft-versus-tumour effect and a higher relapse risk than comparable allogeneic recipients.==</insert>
      <insert timestamp="00:13:33" confidence="13" anchor="**Loci tested (high resolution):** HLA-A, HLA-C, HLA-B, DRB1, DPB1, DQB1 — asses">

&gt; [!note] Lecturer — Donor Matching
&gt; Matched unrelated donors may be identified through a worldwide registry containing approximately 40 million donors.
&gt;
&gt; - Biological parents and children are automatically haploidentical matches.
&gt; - Full siblings have approximately a 50% chance of being haploidentical matches.
&gt; - Potential donors undergo HLA matching using a buccal swab or blood test; donation usually takes approximately half a day and is similar to donating plasma.
&gt; - Matching is more difficult for East African, First Nations Australian, and Torres Strait Islander patients because of greater HLA diversity and fewer registered donors.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="415,436,934,801" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_aec3b68c6369fab2.webp">
        <description>A schematic diagram illustrating the matching of HLA antigens between a donor's bone marrow graft and a recipient. The left side shows 'Bone marrow graft' alleles (A, C, B, DRB1, DPB1, DQB1) pointing towards the right side labeled 'Recipient', which lists the same alleles alongside the text 'High resolution'. A central box details the 'Donor hierarchy: 1. Matched sibling, 2. Matched unrelated, 3. Mismatched donors: Haploidentical, Unrelated (7/8), Cord'.</description>
      </img>
    </images>
  </page>
  <page number="11">
    <text>3) CONDITIONING REGIMENS

• Myeloablative (MA) conditioning
   • Irreversible pancytopenia
   • Stem cell support required to rescue marrow function and prevent aplasia-related death

• Reduced intensity conditioning
   • Spectrum between MA and NMA conditioning
   • Induced cytopenia: may be prolonged requiring stem cell support, OR host-recovery possible with significant morbidity

• Non-myeloablative (NMA) conditioning
   • Minimal cytopenia, does not require stem cell support

Bacigalupo A, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33.

![Figure 1. Classification of conditioning regimens in 3 categories, based on duration of pancytopenia and requirement for stem cell support. Myeloablative fregimens (MA) produce irreversible pancytopenia and require stem cell support. Non myeloablative regimens (NMA) produce minimal cytopenia and does not require stem cell support. Reduced in-tensity regimens (RIC) are regimens which can not be classified as MA nor NMA.](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_1e650d9bdac8d3bf.webp)</text>
    <formatted_text>- **Myeloablative (MA) conditioning**
  - Irreversible pancytopenia
  - Stem cell support required to rescue marrow function and prevent aplasia-related death
- **Reduced intensity conditioning**
  - Spectrum between MA and NMA conditioning
  - Induced cytopenia: may be prolonged requiring stem cell support, OR host-recovery possible with significant morbidity
- **Non-myeloablative (NMA) conditioning**
  - Minimal cytopenia, does not require stem cell support

*Bacigalupo A, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33.*</formatted_text>
    <audio_inserts count="4">
      <insert timestamp="00:15:40" confidence="5" anchor="- Stem cell support required to rescue marrow function and prevent aplasia-relat">
    - ==Myeloablative conditioning is generally used for younger or fitter patients and provides high disease control with rapid donor-cell engraftment, but has higher toxicity and transplant-related mortality.==</insert>
      <insert timestamp="00:16:34" confidence="9" anchor="- Spectrum between MA and NMA conditioning
  - Induced cytopenia: may be prolong">
    - ==Reduced-intensity conditioning uses enough immunosuppression to permit donor-cell engraftment without completely eradicating the recipient’s bone marrow.==
    - ==It is used more often in older or medically compromised patients and has less immediate organ toxicity and reduced transplant-related mortality.==</insert>
      <insert timestamp="00:17:10" confidence="9" anchor="- Minimal cytopenia, does not require stem cell support">
    - ==Non-myeloablative conditioning relies on the graft-versus-tumour effect rather than high-dose chemotherapy or irradiation.==
    - ==Donor T cells eventually eliminate and replace host blood stem cells.==</insert>
      <insert timestamp="00:14:26" confidence="7" anchor="*Bacigalupo A, et al. Defining the intensity of conditioning regimens: working d">

&gt; [!note] Lecturer — Conditioning Purpose
&gt; Conditioning before transplantation for malignant disease reduces tumour burden and provides sufficient immunosuppression to prevent graft rejection.
&gt;
&gt; - Traditional regimens used total-body irradiation and chemotherapy beyond the level at which the patient’s own blood-forming cells could recover.
&gt; - The transplant then acted as a rescue for the immune and bone marrow systems.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="610,215,929,567" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_1e650d9bdac8d3bf.webp" caption="Figure 1. Classification of conditioning regimens in 3 categories, based on duration of pancytopenia and requirement for stem cell support. Myeloablative fregimens (MA) produce irreversible pancytopenia and require stem cell support. Non myeloablative regimens (NMA) produce minimal cytopenia and does not require stem cell support. Reduced in-tensity regimens (RIC) are regimens which can not be classified as MA nor NMA.">
        <description>This chart classifies conditioning regimens into three categories based on the duration of pancytopenia (x-axis) and the requirement for stem cell support (y-axis). The graph is divided into three regions by diagonal lines: 'Non ablative NMA' in the bottom-left corner (minimal to short pancytopenia, no support required), 'myeloablative MA' in the top-right area (short to irreversible pancytopenia, support required), and 'Reduced intensity conditioning RIC' occupying the central band between them.</description>
      </img>
    </images>
  </page>
  <page number="12">
    <text>3) CONDITIONING REGIMENS

Regimen Selection

• Underlying condition
• Disease status
• Recipient co-morbidities
• Risk of rejection (graft source)</text>
    <formatted_text>#### Regimen selection

- Underlying condition
- Disease status
- Recipient co-morbidities
- Risk of rejection (graft source)</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:18:04" confidence="3" anchor="- Risk of rejection (graft source)">
- ==Regimen choice also depends on whether the marrow is malignant or hyperplastic, the recipient’s fitness for intensive treatment, and the degree of HLA disparity between donor and recipient.==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="727,348,904,424" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart" caption="Regimen Intensity Conditioning Therapy">
        <description>A decorative graphic showing a network of pastel-colored dots connected by thin lines on a white background.</description>
      </img>
      <img order="1" bbox="543,588,623,630" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A red arrow pointing to the left.</description>
      </img>
      <img order="2" bbox="747,594,825,634" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A red arrow pointing to the right.</description>
      </img>
    </images>
  </page>
  <page number="13">
    <text/>
  </page>
  <page number="14">
    <text>INDICATIONS FOR STEM CELL TRANSPLANTS

*   Haematological malignancy
    *   ALL, CLL (usually allo)
    *   Plasma cell disorders, HL, NHL (usually auto)
*   Solid tumours (usually auto)
    *   Neuroblastoma
    *   Soft tissue / Ewing sarcoma
    *   Germ cell tumours
    *   Breast cancer
    *   other
*   Immunological Disease
    *   Primary immune deficiency (usually allo)
    *   Autoimmune disorders (usually auto)
*   Other (usually allo)
    *   Thalassemia
    *   Sickle cell disease
    *   Paroxysmal nocturnal haemoglobinuria
    *   Inherited disorders of metabolism
    *   Bone marrow failure</text>
    <formatted_text>- **Haematological malignancy**
  - ALL, CLL (usually allo)
  - Plasma cell disorders, HL, NHL (usually auto)
- **Solid tumours (usually auto)**
  - Neuroblastoma
  - Soft tissue / Ewing sarcoma
  - Germ cell tumours
  - Breast cancer
  - Other
- **Immunological disease**
  - Primary immune deficiency (usually allo)
  - Autoimmune disorders (usually auto)
- **Other (usually allo)**
  - Thalassemia
  - Sickle cell disease
  - Paroxysmal nocturnal haemoglobinuria
  - Inherited disorders of metabolism
  - Bone marrow failure</formatted_text>
  </page>
  <page number="15">
    <text>INDICATIONS FOR STEM CELL TRANSPLANTS

*   Number of HSCT increasing over time
*   Notable increase in autologous HSCT for autoimmune disease since 2009
*   Western Australia allo-HSCT = 70 in 2025, 55 in 2024</text>
    <formatted_text>- Number of HSCT increasing over time
- Notable increase in autologous HSCT for autoimmune disease since 2009
- Western Australia allo-HSCT: 70 in 2025, 55 in 2024</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:19:33" confidence="8" anchor="- Western Australia allo-HSCT: 70 in 2025, 55 in 2024">

&gt; [!note] Lecturer — Transplant Services
&gt; In Western Australia, allogeneic transplants are performed at Fiona Stanley Hospital.
&gt;
&gt; - Autologous transplants may be performed at Royal Perth Hospital and Sir Charles Gairdner Hospital.
</insert>
    </audio_inserts>
  </page>
  <page number="16">
    <text>**PATIENT JOURNEY**

Haematopoietic stem cell transplants</text>
    <formatted_text>*Haematopoietic stem cell transplants — patient journey.*</formatted_text>
    <images>
      <img order="0" bbox="0,133,1000,389" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A decorative background image featuring a pattern of overlapping, translucent blue bubbles or spheres with white highlights.</description>
      </img>
    </images>
  </page>
  <page number="17">
    <text/>
  </page>
  <page number="18">
    <text>**REFERRAL AND WORK-UP TO HSCT PROGRAM**

*   Diagnosis and start initial treatment (induction chemotherapy)
*   Referral to HSCT program, concurrent family donor search
*   Initial consult (HSCT clinic) – may be phone consult
*   Donor search (family $\rightarrow$ unrelated donor)
*   Presentation at HSCT MDT meeting (initial)
*   Referrals / investigations
    *   Echocardiogram &amp; cardiologist review
    *   Pulmonary function tests
    *   **Dental review
    *   Blood tests, kidney and liver function, viruses (HIV, hepatitis, CMV)
    *   CT or bone scans
    *   Pregnancy test

Recovery from induction chemo

![Bone Marrow Donation](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_b16e35d871b865bd.webp)</text>
    <formatted_text>- Diagnosis and start initial treatment (induction chemotherapy)
- Referral to HSCT program, concurrent family donor search
- Initial consult (HSCT clinic) – may be phone consult
- Donor search (family → unrelated donor)
- Presentation at HSCT MDT meeting (initial)
- Referrals / investigations
  - Echocardiogram &amp; cardiologist review
  - Pulmonary function tests
  - Dental review
  - Blood tests, kidney and liver function, viruses (HIV, hepatitis, CMV)
  - CT or bone scans
  - Pregnancy test
- Recovery from induction chemo</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:23:41" confidence="7" anchor="- Recovery from induction chemo">

&gt; [!note] Lecturer — Treatment Timeline
&gt; Induction chemotherapy generally lasts approximately four weeks and may require hospitalisation. If the patient has a good response and no longer requires transplantation, they may be discharged from the transplant pathway.
&gt;
&gt; - Consolidation chemotherapy while the donor is being prepared is generally lower-toxicity treatment delivered over three to five days.
&gt; - This is followed by approximately three weeks at home for recovery, with patients receiving approximately three to four cycles.
&gt; - Approximately six weeks may be required between completion of consolidation chemotherapy and commencement of conditioning chemotherapy to allow healing.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="33,288,274,710" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_b16e35d871b865bd.webp" caption="Bone Marrow Donation">
        <description>An anatomical illustration depicting the process of bone marrow donation, showing a patient lying prone while a biopsy needle is inserted into the hip bone to extract marrow. The diagram details the collection of stem cells from the bone marrow and illustrates their differentiation into red blood cells, white blood cells, and platelets.</description>
      </img>
    </images>
  </page>
  <page number="19">
    <text>**REFERRAL AND WORK-UP TO HSCT PROGRAM**

*   Disease re-assessment (e.g. bone marrow biopsy)
    *   Remission $\rightarrow$ discharged
*   Second HSCT clinic appointment – F2F
    *   Discuss family search result, refer for unrelated donor search if required
*   Consolidation chemotherapy cycle(s) whilst awaiting donor
*   Final F2F clinic review (review of results, donor confirmation, consent)
*   Presentation at HSCT MDT meting (subsequent)
*   Donor available $\rightarrow$ Ward schedules admission for HSCT

![Bone Marrow Donation](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_6bd59a0c5e840405.webp)</text>
    <formatted_text>- Disease re-assessment (e.g. bone marrow biopsy)
  - Remission → discharged
- Second HSCT clinic appointment – face-to-face
  - Discuss family search result, refer for unrelated donor search if required
- Consolidation chemotherapy cycle(s) whilst awaiting donor
- Final face-to-face clinic review (review of results, donor confirmation, consent)
- Presentation at HSCT MDT meeting (subsequent)
- Donor available → Ward schedules admission for HSCT</formatted_text>
    <images>
      <img order="0" bbox="32,290,274,711" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_6bd59a0c5e840405.webp" caption="Bone Marrow Donation">
        <description>This labelled medical illustration depicts the procedure of bone marrow donation, showing a patient lying prone while a biopsy needle is inserted into their hip bone to extract marrow. The graphic details the cellular composition of the aspirated sample, illustrating stem cells and magnified blood components like red blood cells, white blood cells, and platelets.</description>
      </img>
    </images>
  </page>
  <page number="20">
    <text>ALLOGENEIC TRANSPLANT

![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_3bd9f7c295526a56.webp)</text>
    <formatted_text>*Allogeneic transplant.*</formatted_text>
    <images>
      <img order="0" bbox="173,377,859,750" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_3bd9f7c295526a56.webp">
        <description>A timeline diagram illustrating the sequence of events and complications in an allogeneic transplant procedure. The axis marks days relative to day 0, showing pre-transplant conditioning (lightning bolts), stem cell infusion, and subsequent phases labeled with risks such as pancytopenia, infection, organ toxicity, GVHD, and immunosuppression.</description>
      </img>
    </images>
  </page>
  <page number="21">
    <text>Engraftment: blood count recovery

Days
to ANC ≥ 500
Probability
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 10 20 30 40 50 60
Days

Neutrophil
engraftment occurs
when neutrophils
≥ 0.5 x 10⁹

Thomson B G et al. Blood 2000;96:2703-2711

Days
to platelet count ≥ 50,000/mm³
Probability
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 20 40 60 80 100 120 140 160
Days

Platelet engraftment
occurs when platelets
≥ 20 x 10⁹

![Neutrophil engraftment occurs when neutrophils ≥ 0.5 x 10⁹](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_912fd9b77839160c.webp)
![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_29e2cde7caf59b3a.webp)
![Platelet engraftment occurs when platelets ≥ 20 x 10⁹](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_32971c1a1b46fe24.webp)
![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_ecedde5d5c49a869.webp)</text>
    <formatted_text>Engraftment: blood count recovery

#### Neutrophil engraftment

- Figure: probability curve of days to ANC ≥ 500 (x-axis 0–60 days; y-axis probability 0.0–0.9)
- Neutrophil engraftment occurs when neutrophils ≥ 0.5 × 10⁹
- *Thomson B G et al. Blood 2000;96:2703-2711.*

#### Platelet engraftment

- Figure: probability curve of days to platelet count ≥ 50,000/mm³ (x-axis 0–160 days; y-axis probability 0.0–0.9)
- Platelet engraftment occurs when platelets ≥ 20 × 10⁹</formatted_text>
    <audio_inserts count="4">
      <insert timestamp="00:26:16" confidence="3" anchor="- Neutrophil engraftment occurs when neutrophils ≥ 0.5 × 10⁹">

&gt; [!note] Lecturer — Engraftment Recovery
&gt; Neutrophil recovery reduces, but does not immediately eliminate, the risk associated with infection. Platelet recovery may take longer, so patients may remain platelet-transfusion dependent after neutrophils have returned to safer levels.
</insert>
      <insert timestamp="00:26:31" confidence="10" anchor="- Mobilisation — Administer pre-treatment to release blood stem cells from bone ">

&gt; [!note] Lecturer — Stem Cell Collection
&gt; The donor’s stem cells are mobilised using injections of a stimulating factor for approximately five to ten days. The cells are then collected by apheresis or bone marrow aspiration, and may be cryopreserved if collected at another hospital or imported from another country.
</insert>
      <insert timestamp="00:24:15" confidence="19" anchor="- Conditioning — Conditioning the blood stem cells in the laboratory until they ">

&gt; [!note] Lecturer — Conditioning Treatment
&gt; Conditioning usually lasts approximately six to eight days and finishes on day minus two or minus three. Day zero is the day of stem cell infusion.
&gt;
&gt; - Conditioning may be myeloablative, reduced-intensity, or non-myeloablative.
&gt; - Its purposes are to destroy remaining cancer cells, make room in the bone marrow for donor stem cells, and reduce the risk of graft rejection.
</insert>
      <insert timestamp="00:26:10" confidence="6" anchor="- Aplastic Phase — Provide supportive medical treatment for at least 4 weeks as ">

&gt; [!note] Lecturer — Early Post-Transplant Course
&gt; Stem cells are usually infused on a weekday through a central line, with approximately 200–300 mL of graft infused over 20–30 minutes. After infusion, the cells migrate to the bone marrow and immunosuppression is required to prevent graft rejection.
&gt;
&gt; - Toxicity develops over the following days, including diarrhoea, nausea, stomach cramps, oedema, and mucositis.
&gt; - Blood counts become profoundly reduced, neutrophils may fall to zero, and patients may require blood and platelet transfusions and significant analgesia.
&gt; - Patients usually remain in hospital for approximately one to four weeks, followed by initially weekly outpatient reviews.
&gt; - Even after neutrophil recovery, immunity remains low for several months and some patients may continue to require transfusions.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="218,319,474,532" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_912fd9b77839160c.webp" caption="Neutrophil engraftment occurs when neutrophils ≥ 0.5 x 10⁹">
        <description>A step-function chart plotting the probability of neutrophil engraftment (defined as absolute neutrophil count ≥ 500) against time in days. The curve shows a rapid increase in probability between approximately day 10 and day 35, reaching a plateau near 90% by day 45.</description>
      </img>
      <img order="1" bbox="402,551,490,661" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_29e2cde7caf59b3a.webp">
        <description>A microscopic image of a blood smear showing a granulocyte with a segmented nucleus and granular cytoplasm.</description>
      </img>
      <img order="2" bbox="516,322,767,537" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_32971c1a1b46fe24.webp" caption="Platelet engraftment occurs when platelets ≥ 20 x 10⁹">
        <description>A cumulative probability plot titled 'Days to platelet count ≥ 50,000/mm³', with the y-axis labeled 'Probability' (ranging from 0.0 to 0.9) and the x-axis labeled 'Days' (ranging from 0 to 160). A stepwise curve shows a gradual increase in probability starting around day 30, reaching a plateau near 0.8 by day 100.</description>
      </img>
      <img order="3" bbox="700,549,785,668" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_ecedde5d5c49a869.webp">
        <description>A circular microscopic image, likely a scanning electron micrograph (SEM), showing a cluster of cells with textured surfaces. The grey-scale appearance and cellular morphology are characteristic of blood cells or tissue samples at high magnification.</description>
      </img>
    </images>
  </page>
  <page number="22">
    <text>Allogenic Haematopoietic Stem Cell Transplantation

Allogeneic – from another person
➢ Sibling donor – HLA matched brother or sister
➢ Syngeneic – from an identical twin
➢ Unrelated donor – found using a donor registry
➢ Haploidentical – half-matched family member

Patient
NAKIL
Donor Apheresis

Stage 1 Getting ready for treatment
Stage 2 Conditioning treatment
Stage 3 Collecting your donor’s stem cells
Stage 4 Having the transplant
Stage 5 Waiting for new blood cells to grow
Stage 6 Recovering after your transplant

![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_1da355cd5408a9ea.webp)
![Conditioning CT](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_ab93db786d1e3e62.webp)
![Transplantation](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_5e2d4fa820535dc4.webp)
![ENGRAFTMANT](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_add3cc8ebe164d0c.webp)
![Stage 1 Getting ready for treatment Stage 2 Conditioning treatment Stage 3 Collecting your donor’s stem cells Stage 4 Having the transplant Stage 5 Waiting for new blood cells to grow Stage 6 Recovering after your transplant](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_ba0bc8b439c8a2fe.webp)</text>
    <formatted_text>Allogeneic – from another person:

- Sibling donor – HLA matched brother or sister
- Syngeneic – from an identical twin
- Unrelated donor – found using a donor registry
- Haploidentical – half-matched family member

#### Stages of the Transplant

1. Getting ready for treatment
2. Conditioning treatment
3. Collecting your donor's stem cells
4. Having the transplant
5. Waiting for new blood cells to grow
6. Recovering after your transplant

*(Figure: patient and donor apheresis.)*</formatted_text>
    <images>
      <img order="0" bbox="400,286,522,416" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_1da355cd5408a9ea.webp">
        <description>Illustration of a donor undergoing apheresis, with blood drawn from an arm into a collection machine and returned to the body.</description>
      </img>
      <img order="1" bbox="251,513,365,632" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_ab93db786d1e3e62.webp" caption="Conditioning CT">
        <description>Illustration showing a patient lying in a hospital bed with an IV drip stand positioned next to them, depicting the conditioning treatment stage. The word 'NAKIL' is printed above the patient.</description>
      </img>
      <img order="2" bbox="404,507,519,633" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_5e2d4fa820535dc4.webp" caption="Transplantation">
        <description>An illustration of a patient seated in a reclining chair undergoing an apheresis procedure, with tubes connecting to their arms and leading to a blood separation machine.</description>
      </img>
      <img order="3" bbox="544,488,659,631" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_add3cc8ebe164d0c.webp" caption="ENGRAFTMANT">
        <description>This diagram illustrates the concept of engraftment, showing a central stem cell differentiating into various mature blood cell types (depicted as red cells, platelets, and white cells) via branching arrows.</description>
      </img>
      <img order="4" bbox="685,261,968,706" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_ba0bc8b439c8a2fe.webp" caption="Stage 1 Getting ready for treatment Stage 2 Conditioning treatment Stage 3 Collecting your donor’s stem cells Stage 4 Having the transplant Stage 5 Waiting for new blood cells to grow Stage 6 Recovering after your transplant">
        <description>This is a vertical flowchart illustrating the six sequential stages of an allogeneic haematopoietic stem cell transplant process. The steps are colour-coded and arranged from top to bottom: Stage 1 Getting ready for treatment, which branches into parallel processes for Stage 2 Conditioning treatment (patient) and Stage 3 Collecting your donor's stem cells, followed by Stage 4 Having the transplant, Stage 5 Waiting for new blood cells to grow, and finally Stage 6 Recovering after your transplant.</description>
      </img>
    </images>
  </page>
  <page number="23">
    <text/>
  </page>
  <page number="24">
    <text>Autologous Haematopoietic Stem Cell Transplantation

Administer pre-treatment to release blood stem cells from bone marrow into the bloodstream

**Mobilisation**
A Mobilisation
G-CSF
with or without chemotherapy

**Apheresis**
Cryopreservation with or without ex vivo T cell depletion
without T cell depletion
with T cell depletion

Conditioning the blood stem cells in the laboratory until they are required

**Conditioning**
Chemotherapy with or without TBI

with or without
ex vivo T cell depletion

**HSC Infusion**

Provide supportive medical treatment for at least 4 weeks as the immune system rebuilds

**Aplastic Phase**
10-21 days
before
engraftment

**RECOVERY**

![B HSC collection](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_840be319eee2e660.webp)
![C Conditioning regimen](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_71ce4e879a38a484.webp)
![D HSC infusion](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_97ad181b8841db97.webp)
![E Aplastic phase](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_ced0d2747b454f6d.webp)
![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_542e53a926a9e14f.webp)
![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_c359b9099937218e.webp)</text>
    <formatted_text>- **Mobilisation** — Administer pre-treatment to release blood stem cells from bone marrow into the bloodstream
  - G-CSF with or without chemotherapy
- **Apheresis**
  - Cryopreservation with or without ex vivo T cell depletion (without T cell depletion / with T cell depletion)
- **Conditioning** — Conditioning the blood stem cells in the laboratory until they are required
  - Chemotherapy with or without TBI, with or without ex vivo T cell depletion
- **HSC Infusion**
- **Aplastic Phase** — Provide supportive medical treatment for at least 4 weeks as the immune system rebuilds
  - 10–21 days before engraftment
- **Recovery**</formatted_text>
    <images>
      <img order="0" bbox="62,476,176,599" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_840be319eee2e660.webp" caption="B HSC collection">
        <description>An illustration of a patient receiving treatment, featuring an arrow pointing towards the figure labeled 'G-CSF with or without chemotherapy'. The visual depicts the process of mobilising stem cells from the bone marrow into the bloodstream.</description>
      </img>
      <img order="1" bbox="209,476,326,602" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_71ce4e879a38a484.webp" caption="C Conditioning regimen">
        <description>No discernible content is present.</description>
      </img>
      <img order="2" bbox="357,475,475,600" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_97ad181b8841db97.webp" caption="D HSC infusion">
        <description>Labelled diagram showing a stylized illustration of a patient's head and shoulders, accompanied by icons representing chemotherapy (pill) and total body irradiation (radiation symbol). The text within the figure identifies this step as 'Conditioning regimen' involving 'Chemotherapy with or without TBI'. Note that while the slide caption provided is 'D HSC infusion', the crop visually corresponds to label C.</description>
      </img>
      <img order="3" bbox="512,477,630,601" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_ced0d2747b454f6d.webp" caption="E Aplastic phase">
        <description>Labelled diagram showing a patient reclining in a medical chair with an IV drip stand beside them, illustrating the administration of treatment. The figure is labelled 'D' and captioned 'HSC infusion', corresponding to the stem cell infusion step.</description>
      </img>
      <img order="4" bbox="662,475,780,600" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_542e53a926a9e14f.webp">
        <description>A clinical illustration of a bald patient representing the aplastic phase, accompanied by text indicating the duration is 10-21 days before engraftment.</description>
      </img>
      <img order="5" bbox="808,473,928,602" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_c359b9099937218e.webp">
        <description>A schematic diagram illustrating the differentiation of a hematopoietic stem cell (top) into three distinct blood cell lineages: red blood cells, white blood cells/platelets, and lymphocytes. The figure visually represents the concept of stem cell potency and lineage commitment.</description>
      </img>
    </images>
  </page>
  <page number="25">
    <text>AUTOLOGOUS
TRANSPLANT

![Stage 1: Getting ready for treatment Stage 2: Collecting the stem cells Stage 3: High-dose treatment Stage 4: Having the stem cells Stage 5: Waiting for new blood cells to grow Stage 6: Recovering after your transplant](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_5a748514f5464bba.webp)</text>
    <formatted_text>*Autologous transplant.*</formatted_text>
    <images>
      <img order="0" bbox="598,217,939,792" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="diagram" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_5a748514f5464bba.webp" caption="Stage 1: Getting ready for treatment Stage 2: Collecting the stem cells Stage 3: High-dose treatment Stage 4: Having the stem cells Stage 5: Waiting for new blood cells to grow Stage 6: Recovering after your transplant">
        <description>A vertical flowchart illustrating the six stages of an autologous transplant procedure. The process is depicted through colored, rounded rectangular boxes connected by downward-pointing arrows, outlining the sequence from preparation to recovery.</description>
      </img>
    </images>
  </page>
  <page number="26">
    <text/>
  </page>
  <page number="27">
    <text># STRATEGIES TO REDUCE RISK

*   Pre-HSCT testing
*   Choice of conditioning regimen and immunosuppression
*   Antibacterial and pneumocystis prophylaxis (e.g. trimethoprim-sulfamethoxazole = Bactrim®)
*   Antifungal prophylaxis (e.g. fluconazole)
*   Antiviral prophylaxis (e.g. valaciclovir)
*   Infection control measures
*   Immunisation</text>
    <formatted_text>- Pre-HSCT testing
- Choice of conditioning regimen and immunosuppression
- Antibacterial and pneumocystis prophylaxis (e.g. trimethoprim-sulfamethoxazole = Bactrim®)
- Antifungal prophylaxis (e.g. fluconazole)
- Antiviral prophylaxis (e.g. valaciclovir)
- Infection control measures
- Immunisation</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:07:04" confidence="8" anchor="- Immunisation">

&gt; [!note] Lecturer — Autologous Transplant
&gt; In an autologous transplant, the patient’s own stem cells are collected before high-dose chemotherapy, generally cryopreserved, and later reinfused to restore blood-cell production.
&gt;
&gt; - Advantages include no graft rejection risk, no significant GVHD risk, reduced need for immunosuppression, faster immune recovery, less waiting time for a donor, and lower overall risk than allogeneic transplantation.
&gt; - Autologous transplantation has less graft-versus-tumour effect than allogeneic transplantation.
</insert>
    </audio_inserts>
  </page>
  <page number="28">
    <text>**VACCINATIONS**

o INACTIVATED VACCINES = usually commence 6-12 months post-HSCT

o LIVE VACCINES = usually commence at least 24 months post-HSCT
    o Not if active GVHD or receiving immunosuppressive agents

![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_8ebcfee012d61d33.webp)</text>
    <formatted_text>- **Inactivated vaccines** — usually commence 6–12 months post-HSCT
- **Live vaccines** — usually commence at least 24 months post-HSCT
  - Not if active GVHD or receiving immunosuppressive agents</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:28:55" confidence="8" anchor="- Not if active GVHD or receiving immunosuppressive agents">

&gt; [!note] Lecturer — Post-Transplant Vaccination
&gt; During transplantation, patients lose their memory B cells and need to be revaccinated. Patients may describe this as losing their previous blood and repeating childhood vaccination schedules; day zero may be described as a new birthday because the blood and immune system are being rebuilt.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="102,329,370,674" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_8ebcfee012d61d33.webp">
        <description>Clinical photo: A close-up view of a vaccination being administered into the upper arm (deltoid muscle). One hand holds a syringe with a needle inserted under the skin, while the other hand presses a white cotton pad against the injection site.</description>
      </img>
    </images>
  </page>
  <page number="29">
    <text/>
  </page>
  <page number="30">
    <text>MORTALITY

*   Non-relapse mortality ~10-12%
    *   Infection or toxicity
    *   Sharpest increase in first year
*   Relapse mortality ~20-25% at 2 years
*   Greatest risk of death in first 4 years post-transplant: recurrence
*   Other common causes of death: infection*, second cancers*, organ system dysfunction

Increased risk of transplant-related mortality:
o Allogeneic transplant
o Advanced disease status at time of transplant
o Type of donor
o Intensity of conditioning regimen
o Patient age</text>
    <formatted_text>- **Non-relapse mortality** ~10-12%
  - Infection or toxicity
  - Sharpest increase in first year
- **Relapse mortality** ~20-25% at 2 years
- Greatest risk of death in first 4 years post-transplant: recurrence
- Other common causes of death: infection*, second cancers*, organ system dysfunction

#### Increased Risk of Transplant-Related Mortality

- Allogeneic transplant
- Advanced disease status at time of transplant
- Type of donor
- Intensity of conditioning regimen
- Patient age</formatted_text>
    <audio_inserts count="3">
      <insert timestamp="00:30:12" confidence="6" anchor="- **Relapse mortality** ~20-25% at 2 years">

&gt; [!note] Lecturer — Long-Term Survival
&gt; Relapse mortality is related to the graft-versus-tumour effect. Overall survival remains lower than in the general population, with increased mortality for approximately ten to thirty years after transplantation before approaching that of the general population over time.
</insert>
      <insert timestamp="00:30:22" confidence="4" anchor="- Other common causes of death: infection*, second cancers*, organ system dysfun">
- ==Squamous cell carcinoma==
- ==Oral cancer==</insert>
      <insert timestamp="00:33:24" confidence="3" anchor="- Patient age">
- ==Infection==
- ==Treatment toxicity==
- ==Significant comorbidities==
- ==Ongoing immunosuppression==
- ==GVHD==</insert>
    </audio_inserts>
  </page>
  <page number="31">
    <text># **ORAL COMPLICATIONS**

Before, after, and immediately post-transplant</text>
    <formatted_text>Mortality data as above.

Oral complications occur before, after, and immediately post-transplant.</formatted_text>
    <images>
      <img order="0" bbox="0,133,1000,389" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart" caption="Before, after, and immediately post-transplant">
        <description>The image shows a decorative background pattern of overlapping, translucent blue bubbles or spheres against a white backdrop. It appears to be generic stock artwork used for visual styling rather than illustrating a specific scientific concept.</description>
      </img>
    </images>
  </page>
  <page number="32">
    <text>RISKY PATIENTS

Myelosuppression and immunosuppression:
• Disease
• Cancer therapy
• Immunosuppressive regime

![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_4f508e437194fa26.webp)</text>
    <formatted_text>Oral complications occur before, after, and immediately post-transplant.

#### Myelosuppression and Immunosuppression

- Disease
- Cancer therapy
- Immunosuppressive regime</formatted_text>
    <images>
      <img order="0" bbox="118,398,434,674" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="figure" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_4f508e437194fa26.webp">
        <description>A stylized illustration showing a cross-section of a blood vessel or tissue channel against a dark purple background. Inside the reddish-orange channel, numerous teal-colored spherical particles with surface spikes (resembling viruses) and red ring-shaped structures (representing cells or molecules) are scattered throughout.</description>
      </img>
    </images>
  </page>
  <page number="33">
    <text>ORAL
COMPLICATIONS

Affect ~80% of patients

1. Damage to blood cells and immunosuppression
   o infection, bleeding and anaemia-related oral manifestations

2. Cytotoxic therapies to oral tissues
   o direct and indirect effects

![Table 1 Oral complications in hematology-oncology patients and HSCT recipients](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_9921cc52db74afed.webp)</text>
    <formatted_text>Oral complications affect ~80% of patients.

1. Damage to blood cells and immunosuppression
   - Infection, bleeding and anaemia-related oral manifestations
2. Cytotoxic therapies to oral tissues
   - Direct and indirect effects</formatted_text>
    <images>
      <img order="0" bbox="387,240,942,753" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_9921cc52db74afed.webp" caption="Table 1 Oral complications in hematology-oncology patients and HSCT recipients">
        <description>This table categorizes oral complications in hematology-oncology patients and HSCT recipients by tissue type (Mucosa, Salivary glands, Musculo-skeletal, Sensory disturbances, Teeth and gingivae) or as non-tissue-specific manifestations. It lists specific conditions such as mucositis, xerostomia, and dysgeusia, indicating their occurrence during early versus late presentation phases.</description>
      </img>
    </images>
  </page>
  <page number="34">
    <text># ACUTE SIDE EFFECTS
(OF RELEVANCE TO DENTISTRY)

*   **SUSCEPTIBILITY TO INFECTION (including oral)**
    *   Flare of chronic infection (e.g. odontogenic, periodontal)
    *   Reactivation (e.g. oral herpes simplex virus)
    *   Opportunistic (e.g. oral candidiasis)
    *   Systemic (immunocompromised + mucositis)
*   **ORAL &amp; GASTROINTESTINAL MUCOSITIS**
    *   Implications: pain, infection, nutrition, speech, ability for oral care
*   **CYTOPENIAS**
    *   Thrombocytopenia = bleeding risk
    *   Neutropenia / leukopenia = infection risk
    *   Anaemia
*   **DISSEMINATED INTRAVASCULAR COAGULATION**
    *   Anticoagulant prophylaxis
*   **TASTE ALTERATIONS**
*   **ACUTE GRAFT-VS-HOST DISEASE (allo only)**</text>
    <formatted_text>Patients at risk are those with myelosuppression and immunosuppression due to disease, cancer therapy, or immunosuppressive regime; oral complications affect ~80% of patients.

- **Susceptibility to infection (including oral)**
  - Flare of chronic infection (e.g. odontogenic, periodontal)
  - Reactivation (e.g. oral herpes simplex virus)
  - Opportunistic (e.g. oral candidiasis)
  - Systemic (immunocompromised + mucositis)
- **Oral &amp; gastrointestinal mucositis**
  - Implications: pain, infection, nutrition, speech, ability for oral care
- **Cytopenias**
  - Thrombocytopenia = bleeding risk
  - Neutropenia / leukopenia = infection risk
  - Anaemia
- **Disseminated intravascular coagulation**
  - Anticoagulant prophylaxis
- **Taste alterations**
- **Acute graft-vs-host disease (allo only)**</formatted_text>
    <audio_inserts count="4">
      <insert timestamp="00:30:56" confidence="7" anchor="Patients at risk are those with myelosuppression and immunosuppression due to di">

&gt; [!note] Lecturer — Transplant Dental Risk
&gt; Haematology and oncology patients undergoing transplantation are a high-risk dental population. Inadequate management may contribute to:
&gt;
&gt; - Interruption of cancer treatment.
&gt; - Sepsis.
&gt; - Effects on overall prognosis.
</insert>
      <insert timestamp="00:31:32" confidence="3" anchor="Patients at risk are those with myelosuppression and immunosuppression due to di">

&gt; [!note] Lecturer — Additional Risk Factors
&gt; Risk also results from conditioning therapy, post-transplant immune-mediated treatment, neutropenia, thrombocytopenia, and anaemia.
</insert>
      <insert timestamp="00:37:17" confidence="7" anchor="Oral &amp; gastrointestinal mucositis - Implications: pain, infection, nutrition, sp">

&gt; [!note] Lecturer — Mucositis Progression
&gt; Mucositis may progress from oral erythema to ulceration within approximately two weeks of chemotherapy initiation.
</insert>
      <insert timestamp="00:33:40" confidence="9" anchor="Hyposalivation (and associated sequelae): chemo damage, polypharmacy, cGVHD Oste">

&gt; [!note] Lecturer — Osteoporosis Causes
&gt; Osteoporosis risk may be related to altered endocrine function from conditioning regimens and long-term corticosteroid therapy.
</insert>
    </audio_inserts>
  </page>
  <page number="35">
    <text>CHRONIC SIDE EFFECTS
(OF RELEVANCE TO DENTISTRY)

*   IMMUNOSUPPRESSION (allo only)
    *   Ongoing infection risk
    *   Risk of secondary malignancy – heightened at cGVHD sites
*   HYPOSALIVATION (and associated sequelae)
    *   Chemo damage, polypharmacy, cGVHD
*   OSTEOPOROSIS RISK
    *   Bone-altering medications
*   CHRONIC GVHD (allo only)</text>
    <formatted_text>- Susceptibility to infection (including oral): flare of chronic infection, reactivation, opportunistic and systemic infection
- Oral &amp; gastrointestinal mucositis
- Cytopenias
- Disseminated intravascular coagulation
- Taste alterations
- Acute graft-vs-host disease (allo only)

- **Immunosuppression (allo only)**
  - Ongoing infection risk
  - Risk of secondary malignancy – heightened at cGVHD sites
- **Hyposalivation (and associated sequelae)**
  - Chemo damage, polypharmacy, cGVHD
- **Osteoporosis risk**
  - Bone-altering medications
- **Chronic GVHD (allo only)**</formatted_text>
  </page>
  <page number="36">
    <text>CHRONIC SIDE EFFECTS



![Figure 8. Oral candidiasis in patients with oral cGVHD. (A) Florid pseudomembranous candidiasis in a patient using intensive topical clobetasol solution rinses. (B) Thick, plaque-like confluent pseudomembranous candidiasis in a patient using combined clobetasol and tacrolimus solutions. (C) Erythematous candidiasis in a patient with severe cGVHD-associated salivary gland hypofunction and a full maxillary denture. (D) Typical patchy pseudomembranous candidiasis of the palate in a patient rinsing with dexamethasone solution.](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_3ecb17003e2cf2de.webp)
![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_3fb31e095da80bfc.webp)
![Figure 12. Squamous cell carcinoma of the left posterior buccal vestibule in a 14-year-old girl that was 6 years after transplantation, with a prior history of severe mucosal cGVHD. (A) Ulcerated, exophytic, and indurated lesion of the vestibule that was treated with wide excision and chemoradiation therapy. (B) Localized recurrence that was evident within weeks of completion of therapy.](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_2adda5c2e85dc356.webp)
![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_af32bc618c5d555f.webp)
![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_7d0d49dbc6b218ae.webp)
![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_41833408e9e3ab70.webp)</text>
    <formatted_text>- Immunosuppression (allo only): ongoing infection risk; risk of secondary malignancy – heightened at cGVHD sites
- Hyposalivation (and associated sequelae): chemo damage, polypharmacy, cGVHD
- Osteoporosis risk: bone-altering medications
- Chronic GVHD (allo only)</formatted_text>
    <images>
      <img order="0" bbox="217,220,368,376" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_3ecb17003e2cf2de.webp" caption="Figure 8. Oral candidiasis in patients with oral cGVHD. (A) Florid pseudomembranous candidiasis in a patient using intensive topical clobetasol solution rinses. (B) Thick, plaque-like confluent pseudomembranous candidiasis in a patient using combined clobetasol and tacrolimus solutions. (C) Erythematous candidiasis in a patient with severe cGVHD-associated salivary gland hypofunction and a full maxillary denture. (D) Typical patchy pseudomembranous candidiasis of the palate in a patient rinsing with dexamethasone solution.">
        <description>Clinical photo labeled 'A' showing florid pseudomembranous candidiasis in a patient using intensive topical clobetasol solution rinses. The image depicts the oral cavity with widespread, thick white plaques and erythematous mucosa.</description>
      </img>
      <img order="1" bbox="375,220,534,371" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_3fb31e095da80bfc.webp">
        <description>Clinical photo labeled 'B' showing an intraoral view of the buccal vestibule with a distinct, red ulcerated lesion on the mucosa. The surrounding tissue appears indurated and pale, consistent with the description of an exophytic and ulcerated squamous cell carcinoma.</description>
      </img>
      <img order="2" bbox="217,376,376,531" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_2adda5c2e85dc356.webp" caption="Figure 12. Squamous cell carcinoma of the left posterior buccal vestibule in a 14-year-old girl that was 6 years after transplantation, with a prior history of severe mucosal cGVHD. (A) Ulcerated, exophytic, and indurated lesion of the vestibule that was treated with wide excision and chemoradiation therapy. (B) Localized recurrence that was evident within weeks of completion of therapy.">
        <description>Clinical photo: An intraoral view of the hard palate showing a diffuse, erythematous (red) area. The mucosa appears smooth and inflamed, consistent with the appearance of erythematous candidiasis.</description>
      </img>
      <img order="3" bbox="376,375,534,530" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_af32bc618c5d555f.webp">
        <description>Clinical photo: A close-up view of the oral cavity showing the tongue and lower teeth, with a distinct white patchy lesion visible on the lateral surface of the tongue. The image is labeled 'D' in the top left corner.</description>
      </img>
      <img order="4" bbox="219,570,378,725" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_7d0d49dbc6b218ae.webp">
        <description>Clinical photo: An intraoral view of the posterior buccal vestibule and molar region, showing an ulcerated, exophytic, and indurated lesion adjacent to a tooth.</description>
      </img>
      <img order="5" bbox="377,570,535,724" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_41833408e9e3ab70.webp">
        <description>Clinical photo: A close-up view of a patient's mouth, specifically the lower lip and gum line, held open by fingers to reveal the affected area. The image shows significant inflammation and thick, white plaque-like lesions on the oral mucosa and teeth, consistent with pseudomembranous candidiasis.</description>
      </img>
    </images>
  </page>
  <page number="37">
    <text># GRAFT VS HOST DISEASE</text>
  </page>
  <page number="38">
    <text>&lt;div style=&quot;text-align: center;&quot;&gt;&lt;b&gt;GRAFT VS HOST DISEASE&lt;/b&gt;&lt;/div&gt;

&lt;i&gt;“Caused by reaction of the donor-derived immunocompetent cells against the recipient’s tissues”&lt;/i&gt;

Immune cells in the donated tissue (graft) identify the recipient (host) tissues as ‘foreign’, mounting an immune response to ‘reject’ the host’s cells

Tissue damage is caused by the proliferation of donor T cells and release of inflammatory cytokines</text>
    <formatted_text>&gt; &quot;Caused by reaction of the donor-derived immunocompetent cells against the recipient's tissues&quot;

Immune cells in the donated tissue (graft) identify the recipient (host) tissues as 'foreign', mounting an immune response to 'reject' the host's cells.

Tissue damage is caused by the proliferation of donor T cells and release of inflammatory cytokines.</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:34:35" confidence="2" anchor="Tissue damage is caused by the proliferation of donor T cells and release of inf">

&gt; [!note] Lecturer — Transplant Setting
&gt; GVHD is primarily an issue in allogeneic transplantation.
</insert>
    </audio_inserts>
  </page>
  <page number="39">
    <text>**GRAFT VS HOST DISEASE**

Severity depends on:
*   Degree of histocompatibility matching
*   Number of donor T-cells infused
*   Use of immunosuppressant medication
*   Conditioning regimen</text>
    <formatted_text>Severity depends on:

- Degree of histocompatibility matching
- Number of donor T-cells infused
- Use of immunosuppressant medication
- Conditioning regimen</formatted_text>
  </page>
  <page number="40">
    <text>ACUTE VS CHRONIC GVHD

Previously designated purely based on the time frame of occurrence:
Acute had its onset &amp;lt;100 days after transplant
Chronic commenced or persisted &amp;gt;100 days after transplant

Now recognised that they have distinct clinical and pathologic features. 4 subclassifications:
Classic acute (&amp;lt;100 days; only acute features)
Persistent/recurrent/late onset acute (&amp;gt;100 days; only acute features)
Classic chronic (&amp;gt;100 days; only chronic features)
Overlap syndrome (present at any time post transplant; mixed acute/chronic features)</text>
    <formatted_text>Previously designated purely based on the time frame of occurrence:

- Acute had its onset &lt;100 days after transplant
- Chronic commenced or persisted &gt;100 days after transplant

Now recognised that they have distinct clinical and pathologic features. Four subclassifications:

1. Classic acute (&lt;100 days; only acute features)
2. Persistent/recurrent/late onset acute (&gt;100 days; only acute features)
3. Classic chronic (&gt;100 days; only chronic features)
4. Overlap syndrome (present at any time post transplant; mixed acute/chronic features)</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:35:47" confidence="11" anchor="Now recognised that they have distinct clinical and pathologic features. Four su">

&gt; [!note] Lecturer — Changing Definitions
&gt; The former time-based definitions are less useful with reduced-intensity conditioning.
&gt;
&gt; - Acute symptoms may be delayed.
&gt; - Chronic GVHD may occur earlier than expected.
</insert>
    </audio_inserts>
  </page>
  <page number="41">
    <text>FEATURES OF ACUTE GVHD

Acute GvHD
• Principal target organs = skin, GIT, liver
• Skin: usually first and most common site:
  • Maculopapular rash
  • May develop into bullous lesions with toxic epidermal necrolysis
• GIT: diarrhoea, abdominal pain, nausea, vomiting, anorexia, oral mucosal involvement
• Liver: elevated LFTs, elevated cholesterol, painful hepatomegaly, dark urine, pale stool, fluid retention, pruritus
• Less commonly involved organ systems: haematopoietic system, eyes, kidneys, and lung

![Acute graft-versus-host disease Widespread erythema, desquamation, and postinflammatory hyperpigmentation are evident in this patient with acute graft-versus-host disease.](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_22aed25fe646e299.webp)
![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_2e104f81ff422478.webp)</text>
    <formatted_text>- Principal target organs = skin, GIT, liver
- Skin: usually first and most common site
  - Maculopapular rash
  - May develop into bullous lesions with toxic epidermal necrolysis
- GIT: diarrhoea, abdominal pain, nausea, vomiting, anorexia, oral mucosal involvement
- Liver: elevated LFTs, elevated cholesterol, painful hepatomegaly, dark urine, pale stool, fluid retention, pruritus
- Less commonly involved organ systems: haematopoietic system, eyes, kidneys, and lung</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:36:34" confidence="9" anchor="- Skin: usually first and most common site
  - Maculopapular rash
  - May develo">
- ==Rash may begin at the nape of the neck, ears, shoulders, palms, or soles==
  - ==The rash may have a sunburn-like appearance==
  - ==Itching and pain may occur==</insert>
      <insert timestamp="00:36:51" confidence="2" anchor="- GIT: diarrhoea, abdominal pain, nausea, vomiting, anorexia, oral mucosal invol">
    - ==Weight loss==</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="721,208,907,460" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_22aed25fe646e299.webp" caption="Acute graft-versus-host disease Widespread erythema, desquamation, and postinflammatory hyperpigmentation are evident in this patient with acute graft-versus-host disease.">
        <description>Clinical photo showing the back of a patient with widespread erythema, desquamation, and postinflammatory hyperpigmentation characteristic of acute graft-versus-host disease.</description>
      </img>
      <img order="1" bbox="695,538,942,779" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_2e104f81ff422478.webp">
        <description>Clinical photo: A close-up view of a patient's mouth showing severe oral mucosal involvement. The lips are cracked, red, and hemorrhagic with crusting, while the tongue displays multiple irregular areas of desquamation and erythema.</description>
      </img>
    </images>
  </page>
  <page number="42">
    <text># FEATURES OF CHRONIC GVHD

**Chronic GvHD**

*   Immunoregulatory disorder with features of both autoimmunity and immunodeficiency; can affect any organ
*   Clinical manifestations resemble autoimmune collagen vascular diseases
*   ~50% of allo-HSCT patients surviving &gt;1yr develop cGVHD

*   Oral mucosa is the most commonly involved site
*   Two main cutaneous forms:
    *   &lt;u&gt;Lichenoid&lt;/u&gt; – predominates in early cGvHD; generally affects peri-orbital skin, ears, palms, soles, genital mucosa
    *   &lt;u&gt;Sclerodermatous&lt;/u&gt; – inflammatory skin plaques (esp on the extremities) are replaced by areas of fibrosis, causing dimpling and contracture; skin of trunk can contract causing secondary restrictive lung disease

*   Other organ systems: eyes (60%), GIT (dysmotility, pseudo-obstruction, dysphagia, oesophageal ulceration/fibrosis/webbing/stricture); lungs; liver</text>
    <formatted_text>- Immunoregulatory disorder with features of both autoimmunity and immunodeficiency; can affect any organ
- Clinical manifestations resemble autoimmune collagen vascular diseases
- ~50% of allo-HSCT patients surviving &gt;1yr develop cGVHD

#### Cutaneous Forms

Two main cutaneous forms:

- *Lichenoid* – predominates in early cGvHD; generally affects peri-orbital skin, ears, palms, soles, genital mucosa
- *Sclerodermatous* – inflammatory skin plaques (esp. on the extremities) are replaced by areas of fibrosis, causing dimpling and contracture; skin of trunk can contract causing secondary restrictive lung disease

The oral mucosa is the most commonly involved site.

#### Other Organ Systems

- Eyes (60%)
- GIT (dysmotility, pseudo-obstruction, dysphagia, oesophageal ulceration/fibrosis/webbing/stricture)
- Lungs
- Liver</formatted_text>
  </page>
  <page number="43">
    <text>ACUTE VS CHRONIC GVHD

| | Acute GVHD | Chronic GVHD |
| :--- | :--- | :--- |
| Pathophysiology | Apoptosis and necrosis of cells | Inflammatory and fibrotic process reminiscent of autoimmune disease |
| Organs affected | Skin, GIT, liver | Skin, GIT, eyes, lungs, female genital tract, liver |
| Oral involvement | Similar to oral mucositis | Mucosal changes, salivary gland dysfunction, sclerosis (trismus) |

![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_8405ff6be4f05049.webp)</text>
    <formatted_text>| | Acute GVHD | Chronic GVHD |
| :--- | :--- | :--- |
| Pathophysiology | Apoptosis and necrosis of cells | Inflammatory and fibrotic process reminiscent of autoimmune disease |
| Organs affected | Skin, GIT, liver | Skin, GIT, eyes, lungs, female genital tract, liver |
| Oral involvement | Similar to oral mucositis | Mucosal changes, salivary gland dysfunction, sclerosis (trismus) |</formatted_text>
    <images>
      <img order="0" bbox="102,386,894,632" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_8405ff6be4f05049.webp">
        <description>A comparison table contrasting Acute GVHD and Chronic GVHD across three categories: Pathophysiology, Organs affected, and Oral involvement.</description>
      </img>
    </images>
  </page>
  <page number="44">
    <text>ORAL CHRONIC GVHD

o Reported to occur in 45-83% of patients with cGvHD (Imanguli, 2008)
o Classic manifestations: (mimic immune-mediated conditions)
    Lichenoid changes, mucosal atrophy and ulceration – resembles oral lichen planus
    Salivary gland dysfunction – salivary gland infiltrates resemble Sjögren’s syndrome
    Trismus – resembles scleroderma

(Treister, 2012)

![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_77349de748a128de.webp)</text>
    <formatted_text>Reported to occur in 45–83% of patients with cGvHD (Imanguli, 2008).

Classic manifestations (mimic immune-mediated conditions):

- Lichenoid changes, mucosal atrophy and ulceration – resembles oral lichen planus
- Salivary gland dysfunction – salivary gland infiltrates resemble Sjögren's syndrome
- Trismus – resembles scleroderma

*(Treister, 2012)*</formatted_text>
    <images>
      <img order="0" bbox="245,502,913,798" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_77349de748a128de.webp">
        <description>A text table categorizing oral chronic graft-versus-host disease (cGVHD) into three clinical presentations: Oral mucosal cGVHD, Salivary gland cGVHD, and Sclerotic cGVHD. The table lists specific signs and symptoms associated with each presentation in corresponding columns.</description>
      </img>
    </images>
  </page>
  <page number="45">
    <text>MUCOSAL CHANGES IN ORAL CGVHD

• Most common on buccal/labial mucosae and tongue, but can affect any site

• Commonly presents as white striations or plaques, erythema, atrophy, and/or ulceration

• May be asymptomatic, uncomfortable, or painful; may limit oral intake

• Prominent buccal reticular changes $\rightarrow$ sensation of mouth tightness or trismus

![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_13e8d5e44fb093b7.webp)
![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_38cd3f93e6a50910.webp)
![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_156fb1f5dac935d4.webp)
![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_6188b93d77c5f0e0.webp)
![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_02b3c407b622d292.webp)
![](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_cd950e92c048cfff.webp)</text>
    <formatted_text>- Most common on buccal/labial mucosae and tongue, but can affect any site
- Commonly presents as white striations or plaques, erythema, atrophy, and/or ulceration
- May be asymptomatic, uncomfortable, or painful; may limit oral intake
- Prominent buccal reticular changes → sensation of mouth tightness or trismus</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:42:21" confidence="4" anchor="- Most common on buccal/labial mucosae and tongue, but can affect any site
- Com">

&gt; [!note] Lecturer — Oral Manifestations
&gt; Oral chronic GVHD may also cause microstomia, difficulty eating, and an increased risk of dental caries.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="479,437,669,642" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_13e8d5e44fb093b7.webp">
        <description>Clinical photo of the buccal mucosa showing prominent white reticular striations (Wickham striae) against a background of erythema. The tongue is visible on the left side of the image, and dental instruments are present on the right.</description>
      </img>
      <img order="1" bbox="689,309,822,498" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_38cd3f93e6a50910.webp">
        <description>Clinical photo: An intraoral view of the buccal mucosa demonstrating white reticular striations (Wickham's striae) and erythematous patches, consistent with oral chronic graft-versus-host disease.</description>
      </img>
      <img order="2" bbox="826,311,970,498" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_156fb1f5dac935d4.webp">
        <description>Clinical photo: An intraoral view of the buccal mucosa showing characteristic white reticular striations (Wickham striae) interspersed with areas of erythema and ulceration. The image illustrates the mucosal changes associated with oral chronic graft-versus-host disease (CGVHD).</description>
      </img>
      <img order="3" bbox="694,527,973,665" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_6188b93d77c5f0e0.webp">
        <description>Clinical photos labeled A and B showing the tongue with mucosal changes, including white striations or plaques and erythema.</description>
      </img>
      <img order="4" bbox="694,668,830,798" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_02b3c407b622d292.webp">
        <description>Clinical photo: An intraoral view of the ventral surface of the tongue, demonstrating prominent white reticular striations and erythema consistent with oral chronic graft-versus-host disease.</description>
      </img>
      <img order="5" bbox="832,665,971,797" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_cd950e92c048cfff.webp">
        <description>Clinical photo: The dorsal surface of the tongue exhibits prominent white reticular striations and plaques against a background of erythema. These mucosal changes are characteristic of oral chronic graft-versus-host disease (cGVHD).</description>
      </img>
    </images>
  </page>
  <page number="46">
    <text>SALIVARY CHANGES IN ORAL CGVHD

Changes may include chronic salivary gland inflammation, formation of mucoceles and duct blockage, reduced volume of saliva and increased viscosity

Extensive salivary gland involvement can result in total destruction of acinar units, leading to permanent and profound hyposalivation

Both qualitative and qualitative changes are observed



![Figure 6. Salivary gland cGVHD with desiccated appearing palatal mucosa secondary to severe salivary gland hypofunction.](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_ebfce999a6491f0c.webp)
![Figure 7. Rampant cervical dental caries affecting all of the teeth in a patient with cGVHD of the salivary glands. Demineralization changes (arrow) appear chalky white.](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_6d870d59c249be5c.webp)
![Figure 9. Multiple superficial mucoceles of the palate.](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_f866f1f045786920.webp)</text>
    <formatted_text>Changes may include chronic salivary gland inflammation, formation of mucoceles and duct blockage, reduced volume of saliva and increased viscosity.

Extensive salivary gland involvement can result in total destruction of acinar units, leading to permanent and profound hyposalivation.

Both qualitative and quantitative changes are observed.</formatted_text>
    <images>
      <img order="0" bbox="521,340,711,525" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_ebfce999a6491f0c.webp" caption="Figure 6. Salivary gland cGVHD with desiccated appearing palatal mucosa secondary to severe salivary gland hypofunction.">
        <description>Clinical photo showing the hard palate and upper dentition. The palatal mucosa appears notably dry, smooth, and shiny, illustrating the desiccated appearance associated with severe salivary gland hypofunction.</description>
      </img>
      <img order="1" bbox="730,340,922,525" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_6d870d59c249be5c.webp" caption="Figure 7. Rampant cervical dental caries affecting all of the teeth in a patient with cGVHD of the salivary glands. Demineralization changes (arrow) appear chalky white.">
        <description>Clinical photo showing the anterior teeth with extensive chalky white demineralization at the cervical margins, accompanied by inflamed gingival tissue. A black arrow points to a specific area of enamel loss on the upper right lateral incisor.</description>
      </img>
      <img order="2" bbox="617,577,821,774" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_f866f1f045786920.webp" caption="Figure 9. Multiple superficial mucoceles of the palate.">
        <description>Clinical photograph of the hard palate showing multiple small, superficial, translucent vesicles or blisters clustered in the center of the mucosa. The image illustrates mucoceles, which are fluid-filled sacs resulting from salivary gland duct blockage.</description>
      </img>
    </images>
  </page>
  <page number="47">
    <text>SCLEROTIC/FIBROTIC CHANGES IN ORAL CGVHD

Signs &amp; symptoms include: trismus, pain, secondary ulceration, impaired oral hygiene

Can be primarily cutaneous or primarily mucosal:
• Cutaneous: perioral and facial skin sclerosis
• Mucosal: chronic mucosal inflammation $\rightarrow$ fibrosis

Secondary periodontal recession may result $\rightarrow$ dental sensitivity

A
B

![Figure 10. Orofacial sclerotic cGVHD. (A) Fibrous band formation of the right buccal mucosa secondary to long-standing mucosal cGVHD, with limited opening and secondary gingival injury because of tightness. (B) Generalized skin and myofascial fibrosis with intense and painful secondary myospasms and limited opening.](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_fa19f3c1fcf08d33.webp)
![Figure 10. Orofacial sclerotic cGVHD. (A) Fibrous band formation of the right buccal mucosa secondary to long-standing mucosal cGVHD, with limited opening and secondary gingival injury because of tightness. (B) Generalized skin and myofascial fibrosis with intense and painful secondary myospasms and limited opening.](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_8f6b7ac6174e0716.webp)</text>
    <formatted_text>Signs and symptoms include: trismus, pain, secondary ulceration, impaired oral hygiene.

Can be primarily cutaneous or primarily mucosal:

- *Cutaneous*: perioral and facial skin sclerosis
- *Mucosal*: chronic mucosal inflammation → fibrosis

Secondary periodontal recession may result → dental sensitivity.

*(Illustrated images labelled A and B.)*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:41:45" confidence="7" anchor="Secondary periodontal recession may result → dental sensitivity.">

&gt; [!note] Lecturer — Mouth Opening Baseline
&gt; At the pre-transplant examination, maximum inter-incisal opening can be recorded as a baseline. This can be compared with the measurement at approximately 100 days after transplantation, when chronic GVHD may begin to develop and oral involvement becomes more likely.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="205,605,400,795" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_fa19f3c1fcf08d33.webp" caption="Figure 10. Orofacial sclerotic cGVHD. (A) Fibrous band formation of the right buccal mucosa secondary to long-standing mucosal cGVHD, with limited opening and secondary gingival injury because of tightness. (B) Generalized skin and myofascial fibrosis with intense and painful secondary myospasms and limited opening.">
        <description>Clinical photograph labeled 'A' showing the interior of a mouth with restricted opening and visible fibrous band formation on the buccal mucosa. Black arrows point to specific areas of tissue tightness and secondary gingival injury within the oral cavity.</description>
      </img>
      <img order="1" bbox="401,606,594,794" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="photo" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_8f6b7ac6174e0716.webp" caption="Figure 10. Orofacial sclerotic cGVHD. (A) Fibrous band formation of the right buccal mucosa secondary to long-standing mucosal cGVHD, with limited opening and secondary gingival injury because of tightness. (B) Generalized skin and myofascial fibrosis with intense and painful secondary myospasms and limited opening.">
        <description>Clinical photograph showing the lower face of a patient with significant skin tightness and fibrosis around the mouth. The lips appear thin, fixed, and retracted, resulting in limited oral opening (microstomia) and a visible band across the chin.</description>
      </img>
    </images>
  </page>
  <page number="48">
    <text>ORAL SCC AS A COMPLICATION OF CGVHD

*   Allogenic SCT survivors face a significant risk of secondary malignancy:
    *   2-6% develop a secondary solid malignancy at 10 years
    *   1/6 are SCCs of the oral cavity
*   Risk factors: male, Fanconi anaemia, more extensive cGvHD, advanced age at time of transplant, TBI
*   Unclear whether due to the cGvHD itself or prolonged immunosuppression
*   Mucosal surveillance required</text>
    <formatted_text>- Allogenic SCT survivors face a significant risk of secondary malignancy:
  - 2–6% develop a secondary solid malignancy at 10 years
  - 1/6 are SCCs of the oral cavity
- Risk factors: male, Fanconi anaemia, more extensive cGvHD, advanced age at time of transplant, TBI
- Unclear whether due to the cGvHD itself or prolonged immunosuppression
- Mucosal surveillance required</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:43:13" confidence="7" anchor="- Unclear whether due to the cGvHD itself or prolonged immunosuppression
- Mucos">

&gt; [!note] Lecturer — Ongoing Surveillance
&gt; Mucosal surveillance remains important after the patient returns to routine community dental care.
</insert>
    </audio_inserts>
  </page>
  <page number="49">
    <text># MANAGEMENT OF ORAL CGVHD

**Medical Management**
*   Systemic management
*   Topical immunomodulatory therapy:
    *   Topical corticosteroids (gels, ointments, rinses, puffers)
    *   Cyclosporin rinse or paste
    *   Tacrolimus and pimecrolimus (calcineurin inhibitors)

**Sclerosis Management**
*   Physical therapy – low load passive stretching
*   Intralesional steroid therapy
*   Surgery to disrupt mucosal bands or strictures in focal areas

**Dental Considerations**
*   Caries prevention (tailored)
*   Minimise oral trauma and irritation
    *   Well-fitting dentures
    *   Smoothing of sharp teeth/fillings
    *   Avoidance of SLS, ETOH mouthwash
    *   Avoidance of dietary irritants
*   Mucosal surveillance &amp; biopsy as indicated
*   Symptom palliation
    *   Topical analgesics
    *   Mucosal lubricants
    *   Sialagogues (avoid: pulmonary or gastrointestinal GvHD, significant comorbidities)
*   Smoking cessation counselling; moderation of alcohol consumption</text>
    <formatted_text>#### Medical Management

- Systemic management
- Topical immunomodulatory therapy:
  - Topical corticosteroids (gels, ointments, rinses, puffers)
  - Cyclosporin rinse or paste
  - Tacrolimus and pimecrolimus (calcineurin inhibitors)

#### Sclerosis Management

- Physical therapy – low load passive stretching
- Intralesional steroid therapy
- Surgery to disrupt mucosal bands or strictures in focal areas

#### Dental Considerations

- Caries prevention (tailored)
- Minimise oral trauma and irritation
  - Well-fitting dentures
  - Smoothing of sharp teeth/fillings
  - Avoidance of SLS, ETOH mouthwash
  - Avoidance of dietary irritants
- Mucosal surveillance &amp; biopsy as indicated
- Symptom palliation
  - Topical analgesics
  - Mucosal lubricants
  - Sialagogues (avoid: pulmonary or gastrointestinal GvHD, significant comorbidities)
- Smoking cessation counselling; moderation of alcohol consumption</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:23:07" confidence="3" anchor="- Smoking cessation counselling; moderation of alcohol consumption">

&gt; [!note] Lecturer — Treatment Goals
&gt; Treatment is generally directed toward symptom control and patient comfort rather than cure, because chronic GVHD may not be curable.
</insert>
    </audio_inserts>
  </page>
  <page number="50">
    <text># BASIC ORAL CARE

Haematopoietic stem cell and bone marrow transplants</text>
    <formatted_text>Haematopoietic stem cell and bone marrow transplants</formatted_text>
    <images>
      <img order="0" bbox="0,133,1000,389" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A decorative graphic featuring a pattern of large, glossy blue bubbles or spheres against a white background.</description>
      </img>
    </images>
  </page>
  <page number="51">
    <text>BASIC ORAL CARE GUIDELINES

Support Care Cancer (2015) 23:223–236
DOI 10.1007/s00520-014-2378-x

REVIEW ARTICLE

Basic oral care for hematology-oncology patients
and hematopoietic stem cell transplantation recipients: a position
paper from the joint task force of the Multinational Association
of Supportive Care in Cancer/International Society of Oral
Oncology (MASCC/ISOO) and the European Society for Blood
and Marrow Transplantation (EBMT)

Sharon Elad · Judith E. Raber-Durlacher · Michael T. Brennan · Deborah P. Saunders ·
Arno P. Mank · Yehuda Zadik · Barry Quinn · Joel B. Epstein · Nicole M. A. Bijlevens ·
Tuomas Waltimo · Jakob R. Passweg · M. Elvira P. Correa · Göran Dahllöf ·
Karin U. E. Garming-Legert · Richard M. Logan · Carin M.J. Potting · Michael Y. Shapira ·
Yoshihiko Soga · Jacqui Stringer · Monique A. Stokman · Samuel Vokurka ·
Elisabeth Wallbult · Noam Yarom · Siri Beier Jensen

Received: 24 May 2014 / Accepted: 30 July 2014 / Published online: 5 September 2014
© Springer-Verlag Berlin Heidelberg 2014

MASCC/ISOO/EBMT HSCT Haem-
Onc Basic Oral Care 2014

Supportive Care in Cancer (2019) 27:3949–3967
https://doi.org/10.1007/s00520-019-04848-4

SPECIAL ARTICLE

Systematic review of basic oral care for the management of oral
mucositis in cancer patients and clinical practice guidelines

Catherine H. L. Hong¹ · Luiz Alcino Gueiros² · Janet S. Fulton³ · Karis Kin Fong Cheng⁴ · Abhishek Kandwal⁵ ·
Dimitra Galiti⁶ · Jane M. Fall-Dickson⁷ · Jorgen Johansen⁸ · Suzanne Ameringer⁹ · Tomoko Kataoka¹⁰ ·
Dianna Weikel¹¹ · June Eilers¹² · Vinasha Ranna¹³ · Anusha Vaddi¹⁴ · Rajesh V. Lalla¹⁵ · Paolo Bossi¹⁶ · Sharon Elad¹⁷,
On behalf of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International
Society for Oral Oncology (MASCC/ISOO)

Received: 20 January 2019 / Accepted: 30 April 2019 / Published online: 8 July 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Abstract
Purpose The aim of this study was to update the clinical practice guidelines for the use of basic oral care (BOC) interventions for
the prevention and/or treatment of oral mucositis (OM).
Methods A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care
in Cancer/International Society for Oral Oncology (MASCC/ISOO). The body of evidence for each intervention in each cancer
treatment setting was assigned an evidence level. The findings were added to the database used to develop the 2013 MASCC/
ISOO clinical practice guidelines. Based on the evidence level, one of the following three guideline determinations was possible:
Recommendation, Suggestion, No guideline possible.
Results A total of 17 new papers across six interventions were examined and merged with a previous database. Based on the
literature, the following guidelines were possible. The panel suggests that the implementation of multi-agent combination oral
care protocols is beneficial for the prevention of OM during chemotherapy, head and neck (H&amp;N) radiation therapy (RT), and
hematopoietic stem cell transplantation (Level of Evidence III). The panel suggests that chlorhexidine not be used to prevent OM
in patients undergoing H&amp;N RT (Level of Evidence III). No guideline was possible for professional oral care, patient education,
saline, and sodium bicarbonate, and expert opinion complemented these guidelines.

Check for
updates

MASCC/ISOO Oral Mucositis 2019

The Oral &amp; Dental Management
of Patients Before, During and
After Cancer Therapy

Full guidance available at www.rcseng.ac.uk/dental-
facilities/dfs/publications-guidelines/clinical-guidelines

Faculty of Dental Surgery February 2026 v.10 02/26

RCS England Cancer Therapy Oral
Management 2026</text>
    <formatted_text>*Elad S., Raber-Durlacher J.E., Brennan M.T., Saunders D.P., Mank A.P., Zadik Y., Quinn B., Epstein J.B., Bijlevens N.M.A., Waltimo T., Passweg J.R., Correa M.E.P., Dahllöf G., Garming-Legert K.U.E., Logan R.M., Potting C.M.J., Shapira M.Y., Soga Y., Stringer J., Stokman M.A., Vokurka S., Wallbult E., Yarom N., Beier Jensen S. (2014). Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT), Support Care Cancer, 23, 223-236.*

Received: 24 May 2014 / Accepted: 30 July 2014 / Published online: 5 September 2014
© Springer-Verlag Berlin Heidelberg 2014

*Hong C.H.L., Gueiros L.A., Fulton J.S., Cheng K.K.F., Kandwal A., Galiti D., Fall-Dickson J.M., Johansen J., Ameringer S., Kataoka T., Weikel D., Eilers J., Ranna V., Vaddi A., Lalla R.V., Bossi P., Elad S., on behalf of the Mucositis Study Group of MASCC/ISOO (2019). Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines, Support Care Cancer, 27, 3949-3967.*

Received: 20 January 2019 / Accepted: 30 April 2019 / Published online: 8 July 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

#### Abstract

- **Purpose:** The aim of this study was to update the clinical practice guidelines for the use of basic oral care (BOC) interventions for the prevention and/or treatment of oral mucositis (OM).
- **Methods:** A systematic review was conducted by the Mucositis Study Group of MASCC/ISOO. The body of evidence for each intervention in each cancer treatment setting was assigned an evidence level. The findings were added to the database used to develop the 2013 MASCC/ISOO clinical practice guidelines. Based on the evidence level, one of the following three guideline determinations was possible: Recommendation, Suggestion, No guideline possible.
- **Results:** A total of 17 new papers across six interventions were examined and merged with a previous database. Based on the literature, the following guidelines were possible: the panel suggests that the implementation of multi-agent combination oral care protocols is beneficial for the prevention of OM during chemotherapy, head and neck (H&amp;N) radiation therapy (RT), and hematopoietic stem cell transplantation (Level of Evidence III). The panel suggests that chlorhexidine not be used to prevent OM in patients undergoing H&amp;N RT (Level of Evidence III). No guideline was possible for professional oral care, patient education, saline, and sodium bicarbonate, and expert opinion complemented these guidelines.

*The Oral &amp; Dental Management of Patients Before, During and After Cancer Therapy — Faculty of Dental Surgery, February 2026, v.10 — full guidance available at www.rcseng.ac.uk/dental-facilities/dfs/publications-guidelines/clinical-guidelines*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:45:25" confidence="9" anchor="The findings were added to the database used to develop the 2013 MASCC/ISOO clin">

&gt; [!note] Lecturer — Transplant Complications
&gt; Patients undergoing transplantation are at risk of oral complications that may cause substantial morbidity and potentially contribute to mortality.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="724,343,934,586" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart" caption="The Oral &amp; Dental Management of Patients Before, During and After Cancer Therapy">
        <description>A decorative graphic featuring a scattered arrangement of awareness ribbons in various colors, including red, pink, blue, green, purple, yellow, orange, black, and white.</description>
      </img>
    </images>
  </page>
  <page number="52">
    <text>BASIC ORAL CARE

“the activities that should be part of the patient’s routine care during periods of cancer treatment in order to maintain good oral health and reduce the risk for local inflammation and infection, as well as systemic infection originating from the oral cavity”</text>
    <formatted_text>&gt; &quot;the activities that should be part of the patient's routine care during periods of cancer treatment in order to maintain good oral health and reduce the risk for local inflammation and infection, as well as systemic infection originating from the oral cavity&quot;</formatted_text>
  </page>
  <page number="53">
    <text>Before HSCT/CT

**Prevention of infection**
Oral/Dental examination
•Refer for dental evaluation
•Focus: Eliminate foci of infection, traumatic surfaces

**Pain control**
Prevention of local trauma
•Refer for dental evaluation
•Eliminate causes for local trauma

**Maintain oral function**
Chewing capability
•Ask patient about difficulty to chew
•Refer to dentist to restore occlusion, if applicable

**Managing oral complications of the underlying cancer or anti-cancer treatment**
Oral examination
•Refer for an oral medicine specialist / dentist

**Quality of life**
Education
•Inform about future possible oral complications

During HSCT/CT

**Oral hygiene**
•Ensure cleaning teeth and tongue - soft bristled toothbrush - flossing if capable w/o trauma

**Decontamination**
•Advise using bland rinses (e.g., saline), repeated rinses/day
•Advise rinsing with chlorhexidine in alcohol free solution, x2/day
•If unable to rinse, apply solution to sterile gauze or toothette

**Prophylaxis**
•Apply the institute protocol for prophylaxis for oral candidiasis &amp; viral reactivation

**Pain assessment**
•Score consistently (e.g., 0-10 scale/ WHO ladder)

**Diagnosis**
•Consult with an oral medicine / dentist for source of pain

**Pain of dental origin**
•Address using a non-surgical approach

**Treatment**
•Apply the institute protocol for pain control, topical &amp; systemic agents

**Speaking. Oral moisture**
•Utilize:
- sugar free chewing gum/candy (non-acidic)
- dentifrices for oral dryness
- saliva substitute 1st line
- frequent sips of water

**Diet**
•Promote non-cariogenic, low acid atraumatic diet

**Detection**
•Detect possible signs &amp; symptoms
•Consult with oral medicine specialist / dentist treatment

**Taste change**
•Encourage the patient to maintain oral intake

**Dry Mouth**
•Utilize:
- sugar free chewing gum/candy (non-acidic)
- dentifrices for oral dryness
- saliva substitute
- frequent sips of water

**Awareness of future dental problems**
•Educate patient regarding late effects of therapy

After HSCT/CT

**Viral infection**
•Consider anti-viral prophylaxis

**Candidal infection**
•Consider anti-fungal prophylaxis: topical (sugar-free) or systemic

**Dental infection**
•Encourage the patient to have frequent dental recalls

**Oral hygiene**
•Educate &amp; reinforce optimal oral hygiene and dental prevention

**Diagnosis**
•Consult oral medicine / dentist for source of pain

**Timing**
•Consult physician / oral medicine specialist / dentist for best timing for routine dental treatment &amp; any prophylactic measures

**Dry Mouth**
- Maintain good oral hygiene
- use fluoride supplements
- avoid sweets
- visit the dentist regularly

**Limited mouth opening**
•Consider physiotherapy
•Motivate routine dental care
•Encourage oral hygiene

**cGVHD (mucosa, salivary gland)**
•Consult with an oral medicine specialist / dentist for current treatment recommendations
•Motivate patient to keep routine surveillance (risk for SCC)

**Dry Mouth**
•Motivate patients to:
- keep oral hygiene
- use fluoride supplements
- avoid sweets
- visit the dentist regularly
•Utilize:
- sialogogues
- sugar free chewing gum/candy (non-acidic)
- saliva substitute for palliation
- frequent sips of water

Elad S, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015 Jan;23(1):223-36.


![Fig. 1 HSCT haematopoietic stem cells transplantation, CT chemotherapy, WHO world health organization, cGVHD chronic graft versus host disease, SCC squamous cell carcinoma](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_1d10e2deb2de44e8.webp)</text>
    <formatted_text>#### Before HSCT/CT

**Prevention of infection** — Oral/dental examination
- Refer for dental evaluation
- Focus: eliminate foci of infection, traumatic surfaces

**Pain control** — Prevention of local trauma
- Refer for dental evaluation
- Eliminate causes for local trauma

**Maintain oral function** — Chewing capability
- Ask patient about difficulty to chew
- Refer to dentist to restore occlusion, if applicable

**Managing oral complications of the underlying cancer or anti-cancer treatment** — Oral examination
- Refer for an oral medicine specialist / dentist

**Quality of life** — Education
- Inform about future possible oral complications

#### During HSCT/CT

**Oral hygiene**
- Ensure cleaning teeth and tongue — soft bristled toothbrush — flossing if capable w/o trauma

**Decontamination**
- Advise using bland rinses (e.g., saline), repeated rinses/day
- Advise rinsing with chlorhexidine in alcohol-free solution, x2/day
- If unable to rinse, apply solution to sterile gauze or toothette

**Prophylaxis**
- Apply the institute protocol for prophylaxis for oral candidiasis &amp; viral reactivation

**Pain assessment**
- Score consistently (e.g., 0-10 scale / WHO ladder)

**Diagnosis**
- Consult with an oral medicine specialist / dentist for source of pain

**Pain of dental origin**
- Address using a non-surgical approach

**Treatment**
- Apply the institute protocol for pain control, topical &amp; systemic agents

**Speaking, oral moisture**
- Utilize:
  - sugar-free chewing gum/candy (non-acidic)
  - dentifrices for oral dryness
  - saliva substitute (1st line)
  - frequent sips of water

**Diet**
- Promote non-cariogenic, low-acid atraumatic diet

**Detection**
- Detect possible signs &amp; symptoms
- Consult with oral medicine specialist / dentist for treatment

**Taste change**
- Encourage the patient to maintain oral intake

**Dry mouth**
- Utilize:
  - sugar-free chewing gum/candy (non-acidic)
  - dentifrices for oral dryness
  - saliva substitute
  - frequent sips of water

**Awareness of future dental problems**
- Educate patient regarding late effects of therapy

#### After HSCT/CT

**Viral infection**
- Consider anti-viral prophylaxis

**Candidal infection**
- Consider anti-fungal prophylaxis: topical (sugar-free) or systemic

**Dental infection**
- Encourage the patient to have frequent dental recalls

**Oral hygiene**
- Educate &amp; reinforce optimal oral hygiene and dental prevention

**Diagnosis**
- Consult oral medicine specialist / dentist for source of pain

**Timing**
- Consult physician / oral medicine specialist / dentist for best timing for routine dental treatment &amp; any prophylactic measures

**Dry mouth**
- Motivate patients to:
  - keep oral hygiene
  - use fluoride supplements
  - avoid sweets
  - visit the dentist regularly
- Utilize:
  - sialogogues
  - sugar-free chewing gum/candy (non-acidic)
  - saliva substitute for palliation
  - frequent sips of water

**Limited mouth opening**
- Consider physiotherapy
- Motivate routine dental care
- Encourage oral hygiene

**cGVHD (mucosa, salivary gland)**
- Consult with an oral medicine specialist / dentist for current treatment recommendations
- Motivate patient to keep routine surveillance (risk for SCC)

*Elad S., et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015 Jan;23(1):223-36.*</formatted_text>
    <images>
      <img order="0" bbox="74,160,857,816" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="chart" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_1d10e2deb2de44e8.webp" caption="Fig. 1 HSCT haematopoietic stem cells transplantation, CT chemotherapy, WHO world health organization, cGVHD chronic graft versus host disease, SCC squamous cell carcinoma">
        <description>A structured flowchart or matrix organizing oral care protocols for patients undergoing hematopoietic stem cell transplantation (HSCT) and chemotherapy (CT). The chart is divided horizontally into three chronological phases: 'Before HSCT/CT', 'During HSCT/CT', and 'After HSCT/CT'. Vertically, it categorizes management strategies into five key areas: Prevention of infection, Pain control, Maintain oral function, Managing oral complications of the underlying cancer or anti-cancer treatment, and Quality of life.</description>
      </img>
    </images>
  </page>
  <page number="54">
    <text>&lt;div style=&quot;background-color: #e0f2f1; padding: 10px; font-size: 0.8em; margin-bottom: 10px;&quot;&gt;
Elad S, &lt;i&gt;et al.&lt;/i&gt; Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015 Jan;23(1):223-36.
&lt;/div&gt;

# PREVENTION OF INFECTION

**Before HSCT**
*   Oral/dental examination: Eliminate foci of infection, trauma ASAP to allow time for treatment and healing (ideally 2 weeks)

**During HSCT**
*   IF oral hygiene compromised, add CHX as an oral antiseptic
*   Brushing should be continued 2-3 times daily with ultra-soft or soft toothbrush, bristles softened in hot water
*   Brushing with sponge brushes is optional, but less effective in removing plaque (though addition of CHX increases effectiveness)
*   Air-dry toothbrush between uses
*   Toothbrush replaced regularly (e.g. after each neutropenic cycle)
*   *Measures to remove plaque from between teeth, C&amp;Bs or implants, and from tongue, should be continued using familiar devices to pt to avoid self-injury

**After HSCT**
*   May need to avoid invasive dental treatment
*   *Aerosol-generating procedures (e.g. S/C with u/s scaler) should be minimised if immunosuppressed
*   *Immune reconstitution may take months after HSCT (even when haematological status is apparently normal)</text>
    <formatted_text>*Elad S., et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015 Jan;23(1):223-36.*

#### Before HSCT

- Oral/dental examination: eliminate foci of infection and trauma ASAP to allow time for treatment and healing (ideally 2 weeks)

#### During HSCT

- If oral hygiene is compromised, add CHX as an oral antiseptic
- Brushing should be continued 2-3 times daily with ultra-soft or soft toothbrush, bristles softened in hot water
- Brushing with sponge brushes is optional, but less effective in removing plaque (though the addition of CHX increases effectiveness)
- Air-dry toothbrush between uses
- Toothbrush replaced regularly (e.g. after each neutropenic cycle)
- Measures to remove plaque from between teeth, C&amp;Bs or implants, and from the tongue should be continued using devices familiar to the patient to avoid self-injury

#### After HSCT

- May need to avoid invasive dental treatment
- Aerosol-generating procedures (e.g. S/C with u/s scaler) should be minimised if immunosuppressed
- Immune reconstitution may take months after HSCT (even when haematological status is apparently normal)</formatted_text>
    <audio_inserts count="5">
      <insert timestamp="00:31:32" confidence="3" anchor="Oral/dental examination: eliminate foci of infection and trauma ASAP to allow ti">

&gt; [!note] Lecturer — Dental Planning
&gt; Dental planning should account for the patient’s neutropenia, thrombocytopenia, anaemia, conditioning schedule, potential treatment delays, and ability to heal.
</insert>
      <insert timestamp="00:45:54" confidence="3" anchor="Measures to remove plaque from between teeth, C&amp;Bs or implants, and from the ton">
- ==A surgically soft toothbrush may be useful for severe mucositis or fragile oral mucosa because its bristles are softer than those generally available in supermarkets.==</insert>
      <insert timestamp="00:48:01" confidence="6" anchor="Measures to remove plaque from between teeth, C&amp;Bs or implants, and from the ton">

&gt; [!note] Lecturer — Interdental Cleaning
&gt; Patients who are not already familiar with flossing or interdental brushes should not necessarily begin these methods during severe thrombocytopenia. Self-injury may occur.
</insert>
      <insert timestamp="00:49:06" confidence="5" anchor="Aerosol-generating procedures (e.g. S/C with u/s scaler) should be minimised if ">
- ==Ultrasonic scaling aerosolises bacterial biofilm from the teeth and is generally avoided while the immune system is recovering.==</insert>
      <insert confidence="1" anchor="Immune reconstitution may take months after HSCT (even when haematological statu">
- ==Appropriate vaccination and medical follow-up should continue after transplantation.==</insert>
    </audio_inserts>
  </page>
  <page number="55">
    <text>DENTAL WORK-UP PRIOR TO
TRANSPLANT

Haematopoietic stem cell and bone marrow transplants</text>
    <formatted_text>Haematopoietic stem cell and bone marrow transplants</formatted_text>
    <images>
      <img order="0" bbox="0,133,1000,387" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="clipart">
        <description>A decorative background image showing a pattern of overlapping, translucent blue bubbles or spheres with white highlights. The artwork is generic and ornamental, containing no subject-matter information related to the slide's topic.</description>
      </img>
    </images>
  </page>
  <page number="56">
    <text>ORAL FOCI OF INFECTION OF CONCERN PRIOR TO URGENT
MEDICAL TREATMENT

| Focus of infection | | |
| :--- | :--- | :--- |
| | Advanced caries | -Cavities in which excavation may lead to pulpal exposure,&lt;br&gt;-Cavities that can harbor fungal organisms,&lt;br&gt;-Unrestorable carious teeth,&lt;br&gt;-Compromised, large restorations |
| | Moderate/advanced gingivitis and periodontitis | - Furcation involvement greater than II grade,&lt;br&gt;-Advanced tooth mobility,&lt;br&gt;-Periodontal pockets ≥6 mm,&lt;br&gt;-Advanced recession (loss of two-third bone support) |
| | Dental-pulp/periapical pathology | -Nonvital/inflamed dental pulp,&lt;br&gt;-Chronic/acute periapical pathology |
| | Others | -Pericoronitis,&lt;br&gt;-Sub, supra-gingival calculus,&lt;br&gt;-Partially erupted teeth,&lt;br&gt;-Root tips (not fully covered by bone or showing radiolucency),&lt;br&gt;-Cysts,&lt;br&gt;-Mucosal lesions,&lt;br&gt;-Leaking crowns and fillings |
| Local bleeding factors | | -Fractured teeth and/or restorations,&lt;br&gt;-Sharp edges of teeth and/or restorations,&lt;br&gt;-Ill-fitting dentures,&lt;br&gt;-Orthodontic appliances,&lt;br&gt;-Teeth contacting directly to the opposing mucosa |

Boguslawska-Kapala et al. Oral health of adult patients undergoing hematopoietic cell transplantation. Pre-transplant assessment and care. 2017;96;1135-1145.

![Table 1 Potential foci of infection and local trauma/bleeding factors within the stomatognathic system in patients undergoing HCT 12, 15–23](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_23101b41cf2986b9.webp)</text>
    <formatted_text>**Foci of infection**

- **Advanced caries:** cavities in which excavation may lead to pulpal exposure; cavities that can harbor fungal organisms; unrestorable carious teeth; compromised, large restorations
- **Moderate/advanced gingivitis and periodontitis:** furcation involvement greater than grade II; advanced tooth mobility; periodontal pockets ≥6 mm; advanced recession (loss of two-thirds bone support)
- **Dental-pulp/periapical pathology:** nonvital/inflamed dental pulp; chronic/acute periapical pathology
- **Others:** pericoronitis; sub-/supra-gingival calculus; partially erupted teeth; root tips (not fully covered by bone or showing radiolucency); cysts; mucosal lesions; leaking crowns and fillings

**Local bleeding factors**

- Fractured teeth and/or restorations
- Sharp edges of teeth and/or restorations
- Ill-fitting dentures
- Orthodontic appliances
- Teeth contacting directly with the opposing mucosa

*Boguslawska-Kapala et al. (2017). Oral health of adult patients undergoing hematopoietic cell transplantation. Pre-transplant assessment and care, Support Care Cancer, 96, 1135-1145.*</formatted_text>
    <audio_inserts count="2">
      <insert timestamp="00:52:56" confidence="4" anchor="Teeth contacting directly with the opposing mucosa">
- ==Non-healing extraction sites==
- ==Potential sources of infection during acute immunosuppression==</insert>
      <insert timestamp="00:50:04" confidence="4" anchor="*Boguslawska-Kapala et al. (2017). Oral health of adult patients undergoing hema">

&gt; [!note] Lecturer — Treatment Priorities
&gt; The dental work-up focuses on urgent problems rather than necessarily completing all treatment before transplantation.
&gt;
&gt; - Treatment may need to be limited when transplantation is urgent, the patient is medically unstable, or cytopenias make procedures unsafe.
&gt; - Delayed healing and the risks of treatment may outweigh the risks of observing the dental condition.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="155,342,845,778" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_23101b41cf2986b9.webp" caption="Table 1 Potential foci of infection and local trauma/bleeding factors within the stomatognathic system in patients undergoing HCT [12, 15–23]">
        <description>A table listing potential foci of infection and local bleeding factors within the stomatognathic system for patients undergoing hematopoietic cell transplantation (HCT). It categorizes risks into Advanced caries, Moderate/advanced gingivitis and periodontitis, Dental-pulp/periapical pathology, Others, and Local bleeding factors, with specific clinical examples provided for each.</description>
      </img>
    </images>
  </page>
  <page number="57">
    <text>WHEN TIME OR SYSTEMIC CONDITIONS ARE AGAINST YOU...

Support Care Cancer (2018) 26:155–174
165

| Protocol Type Dental Pathology | Complete [19–21] | Partial [24–27] | Minimal/incomplete dental evaluation and/or treatment protocols/not cleared [16, 18] |
| :--- | :--- | :--- | :--- |
| Caries | Restore all teeth | Mild/ moderate caries were restored if time permitted; otherwise these lesions were left alone and observed. | Intervention only if symptomatic |
| Severe Caries/ Pulp involvement/Dental abscess | Root canal treatment OR Extract | | |
| Apical periodontitis | • Retreat&lt;br&gt;• Apicoectomy&lt;br&gt;• Extract | • Symptomatic lesions and lesions ≥5 mm were treated&lt;br&gt;• Asymptomatic lesions and lesions &lt;5 mm were observed | |
| Advanced periodontal disease | Extract teeth with&lt;br&gt;• probing depth ≥ 6 mm&lt;br&gt;• furcation I, II, III | Extract teeth with&lt;br&gt;• probing depth ≥ 8 mm&lt;br&gt;• mobility III&lt;br&gt;• severe inflammation | |
| Mobile primary teeth | Extract teeth with &gt;50% root resorption | Extract teeth with severe mobility and expected to exfoliate within a few weeks. | |
| Partially erupted third molars | Extract | • Asymptomatic teeth were observed&lt;br&gt;• Partially erupted third molars with purulence of pericoronitis were extracted. | |

Hong et al. A systematic review of dental disease management in cancer patients. Support Care Cancer. 2018;26:155-174.

![Table 2 Descriptions of complete, partial and minimal dental evaluation/treatment protocols by dental pathology](L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_1c58bd5cb462995c.webp)</text>
    <formatted_text>| Dental pathology | Complete [19-21] | Partial [24-27] | Minimal/incomplete dental evaluation and/or treatment protocols / not cleared [16, 18] |
| :--- | :--- | :--- | :--- |
| Caries | Restore all teeth | Mild/moderate caries were restored if time permitted; otherwise these lesions were left alone and observed. | Intervention only if symptomatic |
| Severe caries / pulp involvement / dental abscess | Root canal treatment OR extract | | |
| Apical periodontitis | Retreat; apicoectomy; extract | Symptomatic lesions and lesions ≥5 mm were treated; asymptomatic lesions and lesions &lt;5 mm were observed | |
| Advanced periodontal disease | Extract teeth with probing depth ≥6 mm, furcation I, II, III | Extract teeth with probing depth ≥8 mm, mobility III, severe inflammation | |
| Mobile primary teeth | Extract teeth with &gt;50% root resorption | Extract teeth with severe mobility expected to exfoliate within a few weeks | |
| Partially erupted third molars | Extract | Asymptomatic teeth were observed; partially erupted third molars with purulence of pericoronitis were extracted | |

*Hong et al. (2018). A systematic review of dental disease management in cancer patients, Support Care Cancer, 26, 155-174.*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:50:59" confidence="9" anchor="*Hong et al. (2018). A systematic review of dental disease management in cancer ">

&gt; [!note] Lecturer — Time-Limited Treatment
&gt; When treatment time is limited, prioritise acute infection, pain, and bleeding risks, and consider watchful waiting for less urgent disease.
&gt;
&gt; - Treat only if the patient becomes symptomatic when definitive treatment cannot be safely completed.
&gt; - Coordinate procedures with the medical team and consider platelet support where appropriate.
&gt; - Platelet transfusions may not produce a sufficient platelet increment in patients with HLA-related issues.
&gt; - Weigh dental infection risk against poor healing, bleeding, or delaying transplantation.
&gt;
&gt; [!example] Dental Management in Severe Aplastic Anaemia
&gt; A man in his early 30s with aplastic anaemia was assessed approximately five months after 15 teeth had been extracted under general anaesthesia for extensive dental decay.
&gt;
&gt; - He had very poor oral hygiene, brushed his teeth only every few months, and had plaque-related periodontal disease with gingival bleeding.
&gt; - Tooth 25 had grade-three mobility, and the extraction socket at tooth 37 had not healed five months after extraction.
&gt; - He had significant pancytopenia and a platelet count of approximately 8.
&gt; - Ordinarily, tooth 25 would have been extracted before transplantation, but the platelet count was too low for safe extraction. Some guidelines use 30 as a threshold, while 50 was preferred in this clinical setting.
&gt; - Platelets can be transfused immediately before or during dental treatment because they sequester rapidly. In this case, HLA-matching issues prevented a satisfactory platelet increment and the count could not be raised above 30.
&gt; - The non-healed extraction socket raised concern that another extraction might also fail to heal and delay transplantation.
&gt; - The case illustrates that avoiding an invasive procedure can be safer than attempting treatment that may cause severe bleeding, poor healing, or delay transplantation.
</insert>
    </audio_inserts>
    <images>
      <img order="0" bbox="171,372,846,774" bbox_format="xyxy_norm_1000" bbox_origin="top_left" bbox_space="page" type="table" path="L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311_figures/img_1c58bd5cb462995c.webp" caption="Table 2 Descriptions of complete, partial and minimal dental evaluation/treatment protocols by dental pathology">
        <description>This table outlines dental evaluation and treatment protocols categorized by pathology (such as caries, periodontal disease, and mobile primary teeth) across three levels of intervention: Complete, Partial, and Minimal/incomplete. It details specific clinical actions for each condition, ranging from restoring all teeth to extracting those with severe mobility or deep probing depths.</description>
      </img>
    </images>
  </page>
  <page number="58">
    <text># THANK YOU

DR JEE-YUN LEUNG | JEEYUN.LEUNG@UWA.EDU.AU</text>
    <formatted_text>**Thank you.**

Dr Jee-Yun Leung | jeeyun.leung@uwa.edu.au</formatted_text>
  </page>
  <page number="59">
    <text># REFERENCES

Triester N, et al (2012). How we treat oral chronic graft-versus-host disease. Blood 120(17): 3407-3418.

Hull K, et al (2015). Oral chronic graft-versus-host disease in Australia: clinical features and challenges in management. International Medicine Journal 45(7): 702-710.

Yeoh, S-C et al (2019). Oral manifestations of systemic diseases and their treatments. Contemporary oral medicine, ed. Farah, C. S et al. Switzerland, Springer International, pp. 1523-1639.

Elad S, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015 Jan;23(1):223-36.

Hong CHL, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019 Oct;27(10):3949-3967.

Kumar N, *et al*. The Oral Management of Oncology Patients Requiring Radiotherapy, Chemotherapy and/or Bone Marrow Transplantation. London: RCS; 2026. Available from: https://www.rcseng.ac.uk/dental-faculties/fds/publications-guidelines/clinical-guidelines/</text>
    <formatted_text>- *Triester N, et al (2012). How we treat oral chronic graft-versus-host disease. Blood 120(17): 3407-3418.*
- *Hull K, et al (2015). Oral chronic graft-versus-host disease in Australia: clinical features and challenges in management. International Medicine Journal 45(7): 702-710.*
- *Yeoh, S-C et al (2019). Oral manifestations of systemic diseases and their treatments. Contemporary oral medicine, ed. Farah, C. S et al. Switzerland, Springer International, pp. 1523-1639.*
- *Elad S, et al. Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer. 2015 Jan;23(1):223-36.*
- *Hong CHL, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019 Oct;27(10):3949-3967.*
- *Kumar N, et al. The Oral Management of Oncology Patients Requiring Radiotherapy, Chemotherapy and/or Bone Marrow Transplantation. London: RCS; 2026. Available from: https://www.rcseng.ac.uk/dental-faculties/fds/publications-guidelines/clinical-guidelines/*</formatted_text>
    <audio_inserts count="1">
      <insert timestamp="00:33:40" confidence="3" anchor="*Kumar N, et al. The Oral Management of Oncology Patients Requiring Radiotherapy">

&gt; [!note] Lecturer — Transplant Dental Care
&gt; Stem cell transplant patients are complex, and dental care must be adapted throughout the transplant journey.
&gt;
&gt; - Disease status
&gt; - Cytopenias
&gt; - Immunosuppression
&gt; - Conditioning regimen
&gt; - Timing within the transplant journey
&gt; - Risk of infection
&gt; - Risk of bleeding
&gt; - Healing capacity
&gt; - GVHD
&gt; - Long-term oral complications
</insert>
    </audio_inserts>
  </page>
  <footnotes>[^1]: Original PDF page 1: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=1|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.1]]
[^2]: Original PDF page 2: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=2|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.2]]
[^3]: Original PDF page 3: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=3|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.3]]
[^4]: Original PDF page 4: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=4|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.4]]
[^5]: Original PDF page 5: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=5|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.5]]
[^6]: Original PDF page 6: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=6|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.6]]
[^7]: Original PDF page 7: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=7|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.7]]
[^8]: Original PDF page 8: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=8|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.8]]
[^9]: Original PDF page 9: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=9|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.9]]
[^10]: Original PDF page 10: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=10|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.10]]
[^11]: Original PDF page 11: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=11|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.11]]
[^12]: Original PDF page 12: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=12|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.12]]
[^13]: Original PDF page 13: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=13|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.13]]
[^14]: Original PDF page 14: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=14|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.14]]
[^15]: Original PDF page 15: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=15|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.15]]
[^16]: Original PDF page 16: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=16|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.16]]
[^17]: Original PDF page 17: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=17|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.17]]
[^18]: Original PDF page 18: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=18|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.18]]
[^19]: Original PDF page 19: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=19|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.19]]
[^20]: Original PDF page 20: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=20|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.20]]
[^21]: Original PDF page 21: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=21|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.21]]
[^22]: Original PDF page 22: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=22|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.22]]
[^23]: Original PDF page 23: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=23|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.23]]
[^24]: Original PDF page 24: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=24|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.24]]
[^25]: Original PDF page 25: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=25|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.25]]
[^26]: Original PDF page 26: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=26|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.26]]
[^27]: Original PDF page 27: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=27|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.27]]
[^28]: Original PDF page 28: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=28|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.28]]
[^29]: Original PDF page 29: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=29|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.29]]
[^30]: Original PDF page 30: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=30|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.30]]
[^31]: Original PDF page 31: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=31|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.31]]
[^32]: Original PDF page 32: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=32|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.32]]
[^33]: Original PDF page 33: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=33|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.33]]
[^34]: Original PDF page 34: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=34|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.34]]
[^35]: Original PDF page 35: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=35|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.35]]
[^36]: Original PDF page 36: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=36|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.36]]
[^37]: Original PDF page 37: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=37|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.37]]
[^38]: Original PDF page 38: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=38|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.38]]
[^39]: Original PDF page 39: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=39|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.39]]
[^40]: Original PDF page 40: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=40|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.40]]
[^41]: Original PDF page 41: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=41|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.41]]
[^42]: Original PDF page 42: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=42|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.42]]
[^43]: Original PDF page 43: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=43|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.43]]
[^44]: Original PDF page 44: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=44|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.44]]
[^45]: Original PDF page 45: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=45|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.45]]
[^46]: Original PDF page 46: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=46|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.46]]
[^47]: Original PDF page 47: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=47|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.47]]
[^48]: Original PDF page 48: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=48|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.48]]
[^49]: Original PDF page 49: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=49|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.49]]
[^50]: Original PDF page 50: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=50|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.50]]
[^51]: Original PDF page 51: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=51|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.51]]
[^52]: Original PDF page 52: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=52|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.52]]
[^53]: Original PDF page 53: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=53|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.53]]
[^54]: Original PDF page 54: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=54|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.54]]
[^55]: Original PDF page 55: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=55|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.55]]
[^56]: Original PDF page 56: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=56|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.56]]
[^57]: Original PDF page 57: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=57|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.57]]
[^58]: Original PDF page 58: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=58|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.58]]
[^59]: Original PDF page 59: [[L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311.pdf#page=59|L9.1 Transplant Medicine 1 HSCT - DMD3 DENT5311, p.59]]</footnotes>
</document>
